Angiotensin (1–7) Expressing Probiotic as a Potential Treatment for Dementia

Abbi R. Hernandez1,2, Anisha Banerjee1, Christy S. Carter1,2,3,4, Thomas W. Buford1,2,3,4,*

1Division of Gerontology, Geriatrics, and Palliative Care, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States,
2UAB Center for Exercise Medicine, University of Alabama at Birmingham, Birmingham, AL, United States,
3Integrative Center for Aging Research, University of Alabama at Birmingham, Birmingham, AL, United States,
4Nathan Shock Center, University of Alabama at Birmingham, Birmingham, AL, United States

Abstract

Increasing life expectancies are unfortunately accompanied by increased prevalence of Alzheimer’s disease (AD). Regrettably, there are no current therapeutic options capable of preventing or treating AD. We review here data indicating that AD is accompanied by gut dysbiosis and impaired renin angiotensin system (RAS) function. Therefore, we propose the potential utility of an intervention targeting both the gut microbiome and RAS as both are heavily involved in proper CNS function. One potential approach which our group is currently exploring is the use of genetically-modified probiotics (GMPs) to deliver therapeutic compounds. In this review, we specifically highlight the potential utility of utilizing a GMP to deliver Angiotensin (1–7), a beneficial component of the renin-angiotensin system with relevant functions in circulation as well as locally in the gut and brain.

Keywords

Alzheimer’s disease; gut-brain axis; renin angiotensin system; genetically modified probiotic; microbiome; Cognition; MAS1 Receptor; age-related memory loss

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Correspondence: Thomas W. Buford, twbuford@uabmc.edu.

AUTHOR CONTRIBUTIONS

AH, AB, CC, and TB contributed to conceptual framework and writing of this manuscript. All authors contributed to the article and approved the submitted version.

Publisher’s Disclaimer: Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
INTRODUCTION

Life expectancy continues to increase in developed countries worldwide, with persons aged >65 years representing the fastest growing segment of the population (Federal Interagency Forum on Aging-Related Statistics, 2006). Among the most pressing public health issues related to aging is the preservation of cognitive function and the prevention/treatment of dementia (Insel et al., 2013). Over 50 million people suffer from dementia worldwide, of which 30–35 million have Alzheimer’s disease (AD) (World Health Organization, 2019). In addition to the tremendous impact on affected patients and their families, cognitive decline is estimated to cost the healthcare system of the United States between $200–300 billion annually (Hurd et al., 2013). Thus, efficacious treatments for preventing or treating dementia are desperately needed, but to date few therapeutic strategies have shown significant promise. In particular, clinical trials in AD have proven challenging and there are no currently approved therapies which directly target AD pathology. As a result, many have called for fresh approaches to dementia treatment and prevention (Carrillo and Vellas, 2013; Zheng et al., 2015; Fish et al., 2019)—in line with major U.S. National Institutes of Health (NIH) initiatives (Insel et al., 2013). Given the substantial challenge in identifying efficacious treatments, novel research in this area is urgently needed.

To date, most approaches to treat or prevent AD have directly targeted the brain/central nervous system (CNS). In line with the need for fresh approaches, it is possible that alternative strategies are needed that target other physiologic systems beyond the CNS. One prominent possibility is targeting the gut microbiota—the microorganisms which compose the complex microenvironment of the human intestinal tract—given their known roles in neural communication (Hu et al., 2016; Alkasir et al., 2017; Proctor et al., 2017). For instance, studies in neurodegenerative diseases including Parkinson’s (Sampson et al., 2016) and Multiple Sclerosis (Berer et al., 2011) have demonstrated gut-neural communication related to disease pathology. Notably, advanced age is associated with changes to both the composition and stability of gut microbiota (Buford, 2017), and dysregulated microbiota (i.e., dysbiosis) has been is associated with cognitive impairment (Cattaneo et al., 2017; Sun et al., 2019). Multiple studies have also indicated that dysbiosis in frail seniors is associated with chronic systemic inflammation (Buford, 2017)—a hallmark of aging and biomarker of numerous age-related conditions including AD. We reviewed the potential of the gut microbiome as a therapeutic target for age-related cognitive decline (Sun et al., 2019), but original studies remain sparse which target the gut microbiome as a therapeutic site of intervention for AD.

One potential approach which our group is currently exploring is the use of genetically-modified probiotics (GMPs) to deliver therapeutic compounds. GMPs allow for the oral delivery of therapeutic compounds by embedding the compound of interest within a bacterial (i.e., probiotic) strain safe for human consumption. Indeed, several authors have purported the potential benefits and therapeutic applications of GMPs—particularly those from lactic acid bacteria (Bermúdez-Humarán et al., 2013; LeBlanc et al., 2013; Cano-Garrido et al., 2015; Börner et al., 2019; Plavec and Berlec, 2019). Major benefits of this approach to drug delivery include (1) typical inherent benefits of the bacteria itself, (2) ease of production, (3) ability for oral administration due to the ability of the bacteria to survive...
gut digestive processes, and (4) ability to influence both systemic and mucosal immune responses.

In fact, GMPs have already been successfully used to treat Crohn’s disease and ulcerative colitis (Barra et al., 2020), phenylketonuria (Durrer et al., 2017), and irritable bowel syndrome (Shigemori and Shimosato, 2017), among other conditions (Taylor and Lamont, 2005). However, its use in the targeting of cognitive impairment is understudied, though the potential benefits are numerous, as outlined herein. In this review, we specifically highlight the potential utility of utilizing a GMP to deliver Angiotensin 1–7 [Ang(1–7)], a beneficial component of the renin-angiotensin system (RAS) with relevant functions in not only the circulation, but also relevant tissues including the intestines and brain. Though there is ample evidence that this compound is beneficial in many ways, systemic infusion of Ang (1,7) itself is not a feasible option, as it’s half-life would require a near constant infusion (Fyhrquist et al., 1976). Our previous work has demonstrated that oral administration of Ang (1,7)-expressing probiotic [Lactobacillus paracasei (LP) modified to express Ang (1–7); Ang (1–7) GMP] not only increased circulating levels of Ang (1,7), it significantly altered several components of the gut-brain-axis in ways that direct systemic Ang (1,7) administration did not (Carter et al., 2019; Buford et al., 2020). Moreover, oral administration of Ang (1,7) GMP significantly altered microbial richness and diversity within the gut, increased circulating Ang (1,7), decreased circulating AngII, and altered several metabolites of tryptophan metabolism in serum, demonstrating its ability to affect changes beyond those observed within the digestive tract where it was placed. However, these data provide evidence that it is not directly Ang (1,7) itself improving peripheral health, as systemic injections did not have similar effects, but perhaps its ability to improve gut health that then has further reaching secondary effects on other organ systems.

THE GUT MICROBIOME

Once considered the “forgotten organ,” the intestinal microbiota have received a tremendous amount of attention in recent years for their role in human health and disease. Indeed, gut dysbiosis has been implicated in the development of pulmonary (Bruzzese et al., 2014), neurologic (Berer et al., 2011; Hu et al., 2016; Sampson et al., 2016), cardiometabolic, and musculoskeletal conditions (Buford, 2017; Sun et al., 2019).

Notably, the majority of the body’s constitutive immune function is dedicated to maintaining homeostasis with the microbiota—evidenced by the fact that 70% of the body’s lymphocytes reside in the gut-associated lymphoid tissue (Collins et al., 2012). Once thought to contribute primarily to allergic and/or inflammatory intestinal disorders, the gut microbiota are now known to communicate with organs far from the intestine (Belkaid and Naik, 2013; Cohen et al., 2017). In fact, it is now well-established that a complex system of communication exists between the gut microbiota and the CNS.

Indeed, the gut microbiota can communicate with the CNS in several different ways including (1) release of pro-inflammatory cytokines to activate the hypothalamic pituitary adrenal (HPA) axis or directly impact CNS immune activity, (2) production of short chain fatty-acids, (3) release of neurotransmitters, or (4) by modulating tryptophan metabolism...
and downstream metabolites (Figure 1, left) (Sharon et al., 2016; Hampton, 2017; Kennedy et al., 2017; Strandwitz, 2018; Fülling et al., 2019). In summary, the literature to date has demonstrated a critical impact of the microbiota on several CNS processes including myelination, neuroinflammation, regulation of blood-brain barrier integrity, as well as regulation of neurogenesis and accumulation of α-synuclein (Figure 1, right).

Human studies have reported advanced age is associated with gut dysbiosis, which was subsequently associated with cognitive impairment (Cattaneo et al., 2017). More recently, at least one human study reported microbiome alterations in patients with AD (Vogt et al., 2017), while a study in *Drosophila* demonstrated that indeed gut dysbiosis accelerates the progression of AD in the fly model of AD (Wu et al., 2017). Several rodent models of AD have also reported gut microbiome alterations (Brandscheid et al., 2017; Minter et al., 2017; Shen et al., 2017; Zhang et al., 2017; Bäuerl et al., 2018; Chen et al., 2020). These data, coupled with similar findings from other neurodegenerative conditions (Berer et al., 2011; Sampson et al., 2016), suggest that the gut microbiome may be an important target for preserving brain health and combating AD. In line with this concept, at least two small studies have explored the potential of delivering probiotics to treat AD (Akbari et al., 2016; Leblhuber et al., 2018). These studies look to leverage the established actions of probiotics on gut microflora composition, the colon mucus barrier, and systemic immunity to treat AD. Another approach—which we discuss here—is to capitalize upon these inherent benefits of probiotics while simultaneously delivering another therapeutic compound.

Indeed, GMPs have been purported as a highly promising strategy for treating disease (Steidler, 2003; Syvanen, 2003; Paton et al., 2012) as they offer an efficacious method to deliver drugs or other therapeutic proteins with precision and a higher degree of site specificity than conventional drug regimens (Kumar M. et al., 2016). Mucosal administration of therapeutic molecules offers several important advantages over systemic delivery including the possibility of oral administration, fewer secondary effects, and the ability to simultaneously modulate both systemic and mucosal immune responses (Börner et al., 2019). To date, GMPs have been utilized to treat a limited number of conditions including inflammatory bowel disease (Steidler et al., 2003) and hypertension (Yang et al., 2015). Still, the scientific community is in the infancy of exploring the potential for GMPs. To our knowledge, no study to date has leveraged the GMP approach—Ang (1–7) or otherwise—to improve cognition. Thus, a tremendous opportunity exists to leverage existing knowledge and advances in technology within this space.

**DEMENTIA TYPES/GROWING CONCERNS**

Various forms of dementia affect more than 70% of individuals over the age of 70 and cost the United States ~$200 billion in 2010 (Hurd et al., 2013). Furthermore, dementia severely decreases quality of life for both patients and caregivers, and neurologic conditions are the third leading cause of disability globally. While cognitive slowing and difficulty multitasking are hallmarks of normal aging, dementias—including mild cognitive impairment (MCI) and Alzheimer’s disease—result in far greater cognitive impairments.
Often thought of as an intermediary step in the progression of dementia is a disease state known as mild cognitive impairment (MCI). While patients with MCI demonstrate impaired cognitive processes beyond those of normal aging, they are not as severe as individuals with more advanced neurodegenerative disease states. While individuals with MCI are more likely to develop Alzheimer’s disease (AD) and other forms of more advanced dementia than age matched controls (Boyle et al., 2006), there are distinct differences in the microbiome profiles of healthy aged control subjects, those with MCI and those with AD (Liu et al., 2019).

Alzheimer’s disease (AD), one of the most prevalent forms of dementia, currently affects 5.8 million people in the United States and is the sixth overall leading cause of death. Typical AD pathology includes extra cellular deposits of amyloid β-protein (Aβ) and neurofibrillary tangles of hyperphosphorylated tau (Selkoe, 2001), though more recent pathological theories of disease etiology include metabolic factors (de la Monte and Wands, 2008). Inclusion of metabolic factors may be critical to preclinical models and therapeutic interventions for AD, as 80% of people with AD also have metabolic deficits, usually in the form of type II diabetes or insulin resistance (Janson et al., 2004). In addition to neuropathology, chronic inflammation and disruption of immunoregulatory functions precede AD-related cognitive decline (Schmidt et al., 2002). Furthermore, vascular contributions to cognitive impairment in dementia (VCID) likely plays a role in AD etiology (Jagust, 2001; de la Torre, 2004) and there is evidence that the microbiome plays a role in vascular health (Grant and Jönsson, 2019). These links between peripheral health and brain pathology suggest the gut-brain-axis could be an important factor in healthy brain aging and dementias, as each of these areas of peripheral health are influenced by gut health and functioning (Honda and Littman, 2012; Nieuwdorp et al., 2014; O’Mahony et al., 2015; Grant and Jönsson, 2019; Chen et al., 2020; Ragonnaud and Biragyn, 2021).

Indeed, emerging evidence indicates individuals with AD demonstrate an altered microbiome profile with decreased diversity beyond that of age-matched controls (Vogt et al., 2017). Although only two studies to date have implemented a probiotic approach to treatment in human AD patients, results have been promising. For example, probiotic administration for 12 weeks was reported to improve Mini-Mental State Examination (MMSE) scores as well as several markers of metabolic health including insulin sensitivity in AD patients relative to the placebo group (30 participants/group) (Akbari et al., 2016). In an additional study, multispecies probiotic supplementation for 28 days significantly altered serum kynurenine levels, which may influence nervous system function (Leblhuber et al., 2018).

Though not an overt form of dementia, Parkinson’s disease (PD) is another neurodegenerative disease with potential cognitive impacts and affects ~1-million individuals in the United States alone (Marras et al., 2018). Interestingly, one of the earliest complaints in individuals who eventually receive a PD diagnosis is constipation, and PD is associated with slow colonic transit (Sakakibara et al., 2003), increased intestinal permeability (Schwiertz et al., 2018) and by alterations in the RAS (Allen et al., 1992). As with other conditions affecting neurological function, PD patients demonstrate specific alterations in gut microbiome (Tan et al., 2014). While probiotics have been utilized for a
while for the treatment of constipation in PD patients (Cassani et al., 2011), more recent work has investigated the efficacy of probiotic treatment for movement and metabolic parameters in PD (Tamtaji et al., 2019). In this randomized double-blind trial, probiotic supplementation for 12 weeks improved motor symptoms as well as metabolic profiles. Similar motor improvements, as well as cognitive benefits, have been noted in a mouse model of PD (Perez-Pardo et al., 2017). These data from PD further suggest that altering the gut microbiome may influence cognitive outcomes in other neurodegenerative conditions, such as AD.

**ANGIOTENSIN (1–7), THE CNS AND POTENTIAL MECHANISMS THROUGH WHICH ANG (1–7) GMP MAY INFLUENCE COGNITIVE FUNCTION AND PATHOLOGY**

In recent years a number of pleiotropic effects have been ascribed to the renin-angiotensin system (RAS) that extend beyond lowering blood pressure (Sica, 2011; Zoccali and Mallamaci, 2014). As we reviewed (Simon et al., 2015), beneficial impacts of the RAS may be induced not only by antagonizing the vasoconstrictive actions of angiotensin II (AngII) binding to the AT$_1$ receptor (AT$_1$R), but also by the more recently discovered Ang (1–7) axis whereby the binding of Ang (1–7) to the Mas (AT$_7$) receptor promotes several beneficial actions (Figure 2, left). However, the vascular effects of RAS-affecting compounds should not be completely ignored, as individuals with AD often present with underlying vascular impairment (Jagust, 2001; de la Torre, 2004).

Among the purported benefits of the Ang (1–7) axis is improved brain health. Components of the axis are found throughout the central nervous system (CNS) including within neurons, astrocytes, cerebral arteries, and various brain regulatory centers including the paraventricular nucleus (PVN) and hypothalamus (Hamming et al., 2004; Gallagher et al., 2006; Becker et al., 2007; Doobay et al., 2007; Guo et al., 2010). Notably, Ang (1–7) stimulates numerous molecular pathways responsible for beneficial adaptations which could contribute to improved cognitive function including increased (1) endothelial nitric oxide synthase (eNOS), (2) brain-derived neurotrophic factor (BDNF), and (3) vascular endothelial growth factor (VEGF) as well as reduced production of reactive oxygen species and pro-inflammatory cytokines (Figure 2, right) (Passos-Silva et al., 2013; Jiang et al., 2014; Zheng et al., 2014; Wang et al., 2016; Kamel et al., 2018).

In line with these actions, evidence from both human and rodent models indicates that Ang (1–7) axis modulation benefits multiple aspects of cognition in several models of cognitive dysfunction, including AD (Kehoe et al., 2016; Wang et al., 2016; Hay et al., 2017, 2019; Kangussu et al., 2017; Kamel et al., 2018). Notably, animal studies have shown remarkable consistency across both loss and gain of function genetic models as well as via pharmacologic stimulation of the Ang (1–7) axis. Moreover, at least two human studies have proposed both systemic (Jiang et al., 2016) and brain (via post-mortem study; Kehoe et al., 2016) Ang (1–7) axis activity as biomarkers of AD pathology including association with amyloid-$\beta$ and tau. Additionally, the plasma membrane glycoprotein neprilysin—in involved in endogenous production of Ang (1–7)—reduces amyloid-$\beta$ and improves memory in mice.
and drosophila (Hüttenrauch et al., 2015; Turrel et al., 2017). These data suggest that Ang (1–7) administration could hold promise for preserving cognitive function in late life as well as in combating AD.

Currently, recombinant Ang (1–7) is being utilized in clinical trials for clinically-urgent conditions including inoperable tumors, breast cancer, mitigation of chemotherapy induced bone marrow toxicity, and wound healing (Source: www.clinicaltrials.gov). However, systemic delivery of Ang (1–7) typically requires burdensome infusions and/or repeated injections as well as the expensive and cumbersome production process for the drug. Thus, a different formulation—particularly one which could be administered orally—could provide practical benefits to patients from both a cost and ease of use standpoint. In line with this reasoning, our previous work has demonstrated that orally delivered Ang (1,7) GMP influences far beyond the gut, including altering levels of neurotransmitters and components of the RAS (Buford et al., 2020).

ANGIOTENSIN (1–7) AND THE GUT

Components of the Ang (1–7) axis are also present throughout the gut including the small intestinal brush border, muscularis mucosa, and propria, as well as microvascular endothelium and vascular smooth muscle cells (Hamming et al., 2004). In fact, the highest tissue concentrations of mRNA for ACE2—the enzyme responsible for producing Ang (1–7) endogenously—are found in the terminal ileum, duodenum, and colon (Tipnis et al., 2000; Harmer et al., 2002). As a result, ACE2 has received attention for its connection to the gut microbiome (Perlot and Penninger, 2013; Cole-Jeffrey et al., 2015; Raizada et al., 2017).

One critical link of gut Ang (1–7) to CNS function is in the metabolism of the essential amino acid tryptophan (Figure 3). Under normal conditions, gut microbiota directly metabolize ~5% of ingested tryptophan into various bioactive compounds related to the intercellular signaling molecule indole. Indole derivatives can have beneficial or toxic effects, and the regulation of derivative production is dependent upon the composition of the intestinal microbiota.

The remaining (~95%) tryptophan is then metabolized by the human host and absorbed in the intestines for transport to the liver and release into the circulation. Once into the circulation, a minority of tryptophan is broken to support protein synthesis and the production of the neurotransmitter serotonin. Meanwhile the vast majority of tryptophan is metabolized to the neuro-regulatory kynurenine pathway—which has been proposed a key link between gut dysbiosis and various neurologic conditions including AD (Widner et al., 2000; Gulaj et al., 2010). Indeed, downstream metabolites of kynurenine are key CNS signaling molecules providing either neuroprotective or neurotoxic effects to the brain. Notably, members of the genus Lactobacilli promote the production of Indole-3-carboxaldehyde (I3A) which promotes the production of interleukin 22 and the maintenance of mucosal reactivity (Zhang and Davies, 2016). Meanwhile, ACE2 is essential to intestinal absorption of tryptophan (Hashimoto et al., 2012; Singer et al., 2012) as well as in regulating intestinal immune function, ecology of the gut microbiome, and attenuating intestinal
inflammation suffered in response to epithelial damage (Singer et al., 2012). Thus, both *Lactobacilli* and Ang (1–7) hold promise for altering these neuro-regulatory pathways.

We recently published data from a short-term dosing study indicating that the Ang (1–7) GMP reduced neuroinflammatory gene expression in the pre-frontal cortex while also increasing circulating concentrations of neuroregulatory compounds picolinic acid and serotonin in older F344/BN rats (Buford et al., 2020). Our findings also indicated that the use of an Ang (1–7)-expressing GMP was more efficacious than subcutaneous injection of a synthetic Ang (1–7) peptide, further suggesting the possible utility of the GMP-based approach. Still, these studies were short-term in an animal model without overt dementia, thus continued exploration is needed in this area to document the full potential utility of this intervention in the preservation of cognitive function—particularly in models of AD.

**EARLY STUDIES OF RAS-AFFECTING COMPOUNDS IN PRE-CLINICAL AND CLINICAL AD**

Much of the previous work manipulating the RAS in preclinical animal models (see Table 1) has utilized one of two categories of drugs, angiotensin receptor blockers (ARBs) and angiotensin converting enzyme inhibitors (ACEI). While both categories of drugs target the same biochemical pathway, ARBs work by blocking AngII from binding to its receptor, AT1R, while ACE inhibitors block the conversion of AngI to AngII (Wright et al., 2013). Both ARBs and ACEIs shift activity of the RAS system away from the AT1-mediated axis toward the Mas-mediated axis (see Figure 2), and therefore may be efficacious in protecting the neurophysiological milieu from various cognitive deficits (see Figures 2, 3).

ARB utilization in preclinical animal models of AD has demonstrated both neuro- and vaso-protective effects when delivered chronically. Intranasal administration of candesartan, a particularly potent and blood brain barrier-permeable ARB, for 8 weeks in a 5XFAD mouse model of familial AD was anti-inflammatory, as it reduced hippocampal microglial activation and Aβ pathology (Torika et al., 2018). However, an amyloid precursor protein (APP) mouse model utilizing candesartan did not observe altered Aβ pathology (Trigiani et al., 2018), suggesting not all AD preclinical models respond similarly to ARBs. While there were partial memory enhancing effects of the ARB losartan in APP mutated mice, these effects were ameliorated by selective blockade of angiotensin IV (AngIV) at its receptor (AT4R), implicating the angiotensin IV/AT4R cascade as a promising candidate for AD intervention (Royea et al., 2017). Because telmisartan is also a peroxisome proliferator-activated receptor (PPAR)-γ agonist capable of exerting anti-inflammatory effects in neurons, these results indicate it may be a particularly useful ARB for the treatment of AD through its combined PPAR-γ and AT1R blockades, resulting in attenuated Aβ deposition (Mogi et al., 2008) and improved cognitive outcomes (Tsukuda et al., 2009). Other ARBS, including valsartan and eprosartan, demonstrated no effect on Aβ or APP pathology (Ferrington et al., 2011, 2012), though results are mixed (Wang et al., 2007), so caution should be taken when selecting an ARB to utilize in preclinical AD trials.

Several studies have also demonstrated great efficacy of ACEIs in pre-clinical AD rodent models. In particular, centrally-active ACEIs, such as perindopril, prevent AD-associated...
cognitive decline, hippocampal microglial & astrocytic activation, and oxidative stress in these animal models utilizing intracerebroventricular Aβ injections, even after as little as 1–7 days of treatment (Yamada et al., 2010; Dong et al., 2011). In contrast, ACEIs that are not centrally active, such as imidapril and enalapril, are ineffective under these same conditions (Yamada et al., 2010; Dong et al., 2011). Longer term administration of perindopril or captopril (also centrally active) delivered intranasally can also improve amyloid burden (Torika et al., 2016), demonstrating feasibility of delivering these compounds peripherally rather than intracerebrally. However, orally delivered captopril did not influence Aβ or APP pathology after 2 (Ferrington et al., 2011) or 6 (Ferrington et al., 2012) months of administration in 3xTgAD mice. Notably, the aforementioned ARB and ACEI studies all utilized young adult animal models of AD. However, it is imperative that aged animals be included in future investigations of the effects of RAS-affecting compounds in AD-related research, as translational studies will not be conducted in young humans, but within the aged population naturally afflicted by this disease state.

The rationale for targeting RAS through a GMP includes not only the aforementioned promising effects of ACE-affecting drugs, but also the interaction between AD and the gut microbiome as demonstrated by animal models. Not only is the gut microbiome of APP transgenic mice significantly shifted, but germ free APP transgenic mice demonstrate significantly reduced Aβ pathology (Harach et al., 2017; Minter et al., 2017). Similarly, overexpression of α-synuclein, which normally results in Parkinson’s-like phenotypes, in germ free mice result in significantly reduced pathological and physical burden (Sampson et al., 2016). Treatment with antibiotics capable of inducing prolonged shifts in gut microbiota also influences neuroinflammation and amyloidosis in a APP/PS1 mouse model (Minter et al., 2016), further suggesting a link between microbiota and AD-related pathology. Work by Kumar et al. demonstrates that there is a potential protective, antimicrobial role for Aβ pathology, thus demonstrating a possible microbial basis for triggering Aβ pathology (Kumar D. K. V. et al., 2016). All together, these data demonstrate that translating RAS-affecting manipulations to humans must not only be easily feasible, but may be particularly effective when it targets the gut. Additional evidence for the link between the RAS and AD is reviewed in Kehoe (2018).

On the other hand, human studies on the influence of angiotensin on AD are sparse, positive outcomes have been reported using ACE inhibitors and ARBs clinically (Quitterer and AbdAlla, 2020). ACEI use is capable of slowing cognitive decline in individuals diagnosed with AD (O’Caoimh et al., 2014), particularly within the first 6 months (Gao et al., 2013). Continuous, or even intermittent, ACEI use over 4 years by individuals with AD lead to significantly less decline in MMSE scores relative to those who had never used ACEIs, including individuals on other antihypertensive drugs (Soto et al., 2013). In a group of individuals with both AD and hypertension, prolonged ARB administration increased Aβ1–42, decreased IL-1β and TNF-α and improved cognitive scores relative to controls administered a calcium channel blocker for the same duration (Wei et al., 2012). Among veterans with cardiovascular disease, individuals prescribed an ARB that developed AD were slower to require assisted living than AD control patients (Li et al., 2010). Furthermore, a combination of diuretics, calcium channel blockers and ARBs slow cognitive decline (Hu et al., 2018), indicating the potential for synergistic interventions
targeting multiple systems. In fact, there is evidence that ARBs may be more effective than ACEIs in regard to cognitive outcomes, independent of their ability to lower blood pressure (Hajjar et al., 2020). However, the optimal timeframe of delivery for ARBs and ACEIs is unclear. While these studies include examples of slowing of already present cognitive decline, whether earlier and/or longer term administration of either class of drug could be preventative of AD and other dementias is unknown, but is worth considering in future endeavors.

POTENTIAL MECHANISMS OF ANG (1,7) GMP EFFICACY

The aforementioned preclinical and clinical studies demonstrate the potential of RAS-affecting compounds for the treatment of AD and dementia. However, a probiotic with not only the ability to target these systems, but to restore gut dysbiosis, such as the Ang (1,7)-expressing *Lactobacillus paracasei* (LP), may provide a better way to target AD and age-related dementia. Moreover, the delivery of therapeutic compounds through probiotics is particularly useful due to their ability to survive gastric acids and bile, allowing them to reach the intestinal target. The specific GMP discussed here utilized LP as the live vector for oral delivery. The LP was then modified to express Ang (1,7) as a secreted fusion protein utilizing cholera toxin subunit B (the non-toxic subunit; CTB), which functions as a trans-epithelial carrier, allowing for uptake into circulation (Verma et al., 2020). Although there is little evidence that oligopeptides, other than di- and tripeptides, can normally cross the mucosal border (Miner-Williams et al., 2014), CTB is able to facilitate transmucosal transport through GM1 receptor mediated endocytosis (Baldauf et al., 2015; Verma et al., 2020). Once this conjoined molecule is secreted into the circulatory system, the CTB is separated from the Ang (1,7) through a furin cleavage site. Expression of Ang (1,7) itself, within several tissues and in serum, has previously been confirmed in mice and rats (Carter et al., 2019; Verma et al., 2020). It is likely that the effects on peripheral and CNS health are synergistic, as they are densely interconnected. There are several mechanisms by which Ang (1,7) GMP may be beneficial for AD, including, but not limited to (1) improved vascular health through the RAS, (2) improved gut dysbiosis, (3) altered neurotransmitter metabolism within the gut and (4) improved glucose metabolism.

**Improved Vascular Health**

First and foremost, the vascular effects of any RAS-affecting compound should be considered. Direct application of the Ang (1,7) GMP into the gut is able to get into circulation (Verma et al., 2019; Buford et al., 2020), where it may then mimic the effects of ARBs and ACEIs through the downregulation of the vasoconstrictive arm of the RAS. The resulting vasodilation may lead to an improvement in AD-related impairments, as many individuals with AD also experience impaired cardiovascular function (Jin et al., 2017). Therefore, this RAS-targeting probiotic may rescue or reduce the cognitive phenotype associated with vascular dementia. However, differentiation between improved neural function and vascular function has yet to be established, though the two are likely synergistically improving outcomes as peripheral and cognitive health are strongly and reciprocally linked.
Repairing Gut Dysbiosis

It is conceivable that the actions of Ang (1,7) GMP work to improve CNS function through the targeting other peripheral tissues, rather than through targeting the brain directly. Impaired gut function can impair brain health and cognitive functioning, and may result in neurodegenerative conditions (Berer et al., 2011; Gareau, 2014; Sampson et al., 2016; Cattaneo et al., 2017), so it is plausible that the restoration of gut health would ameliorate these deficits. The probiotic itself, *Lactobacillus paracasei*, may be able to restore dysbiosis (Kim et al., 2019), which is present in individuals with AD. Both the ACE2/Ang (1,7)/MAS1 axis of the RAS and the probiotic help to reduce inflammation (Gaddam et al., 2014; Wang et al., 2020), which may then decrease gut leakiness and prevent the ability of inflammatory markers and amyloid proteins from escaping into circulation (Pistollato et al., 2016).

Altered Neurotransmitter Metabolism

The intestinal tract is an integral part of many bodily systems, including the nervous system through the generation of many neurotransmitter molecules (Yano et al., 2015; Pistollato et al., 2016). While alterations in gut health may influence the metabolism of several neurotransmitters, RAS activity within the gut is particularly involved in tryptophan, and thus serotonin, metabolism (Figure 1, left) (Sharon et al., 2016; Hampton, 2017; Kennedy et al., 2017; Strandwitz, 2018; Fülling et al., 2019). Additionally, *lactobacillus* supplementation is capable of modulating the neurotransmitter GABA receptor expression, regulating emotional behavior in mice via the vagal nerve (Bravo et al., 2011).

Repaired Glucose Metabolism

Unfortunately, there is both an age- (Gage et al., 1984; Rasgon et al., 2005; Goyal et al., 2017) and AD-related (Janson et al., 2004) reduction in the ability to metabolize glucose, which further impairs cognitive function in these conditions. The ACE2/Ang (1,7)/MAS1 axis of the RAS plays a significant role in glucose absorption through the intestines and activation of this pathway improves hyperglycemia in diabetic patients (Wong et al., 2007; Garg et al., 2012). Furthermore, administration of ACEIs can ameliorate type 2 diabetes (Henriksen, 2007; Favre et al., 2015) and improve obesity (Kouyama et al., 2005; Weisinger et al., 2009).

In addition to the RAS component of the GMP, the probiotic utilized to deliver the compound may improve metabolic function itself. *Lactobacillus paracasei* and other *Lactobacilli* have complex microbiome-metabolome interactions, influencing short chain fatty acid, ketone and methyl acetate concentrations (Martin et al., 2008; Vitali et al., 2010; Arora et al., 2013). Furthermore, these strains are able to increase amino acid absorption as well as beneficially alter the fermentation process (Ndagijimana et al., 2009). *Lactobacillus* itself is capable of improving glucose and insulin signaling in mouse models of obesity and diabetes (Yun et al., 2009; Naito et al., 2011), which are both common comorbidities with AD.
POTENTIAL MODULATORS OF EFFECT NEEDING CONSIDERATION IN STUDY DESIGNS

Biological Sex

A vast gender disparity exists in Alzheimer’s disease (AD), with two-thirds of diagnosed patients being female. Notably, this gender discrepancy is not explained by increased life expectancy as the incidence, cognitive decline, and amyloid pathology are all greater in women compared to age-matched men with AD (Barron and Pike, 2012). As a result, a significant need exists to investigate mechanisms which might contribute to these sex differences in the incidence of AD.

Notably, prior evidence indicates that male and female rats have differing circulating and renal levels Ang (1–7) and other non-classical components of the RAS (Sullivan et al., 2010). Specifically, male mice and rats both demonstrate an increased vascular response to AngII administration than their female counterparts (Tatchum-Talom et al., 2005). Additionally, female spontaneously hypertensive rats (SHRs) have decreased sensitivity to angiotensin II, demonstrating blunted hypertensive effects (Sullivan et al., 2010). This effect is mediated by the RAS system, as ACE inhibitor enalapril administration similarly reduced blood pressure levels in both sexes (Reckelhoff Jane et al., 2000).

Of particular note to those interested in studying age-related disease states such as dementia, there are sex-specific changes in serum peptidases comprising the RAS that accompany aging in humans (Fernández-Atucha et al., 2017). While aminopeptidase A (APA) was the only significantly different peptide across all men and women studied, both APA and ACE were significantly lower in male subjects when only individuals over the age of 55 were included in the analysis. Additionally, estrogen mediates neuroprotection in clinical and animal models of Parkinson’s disease, likely through inhibition of the RAS, as estrogen inhibits nigral angiotensin, mediating neuroprotection (Labandeira-Garcia et al., 2016).

Further consideration should be taken for sex differences in gut microbiota, termed the “microgenderome” by Flak et al. (2013). This concept outlined sex differences in the bidirectional interactions between gut microbiota and the body, particularly in the case of hormones and immunity. However, it should be noted that differences in microbiome composition across male and female humans are confounded by conflicting reports, with opposite changes described across differing cohorts (Vemuri et al., 2019). In any case, estrogen level in males and postmenopausal females correlate with microbiome diversity and richness, though this correlation is absent in pre-menopausal females (Flores et al., 2012). Additionally, males and females may respond to probiotic treatment differently in both humans (Lönnermark et al., 2015) and rodents (McCabe et al., 2013). Together, differences in the RAS and microbiome across male and female subjects warrant additional research and consideration in probiotic-based interventions, particularly in the case of a RAS-targeting GMP.
Diet

Dietary intake is universally considered one of, if not the, most important factor influencing the gut microbiome. Moreover, dietary interventions including caloric restriction, altered macronutrient ratios and intermittent fasting have strong effects in promoting healthy aging. Thus, the choice of diet could have critical implications for determining if results observed with the GMP will translate to humans. However, there are several drivers of altered dietary patterns in older adults leading to decreased diversity in foods consumed, including decreased physical mobility, loss of smell or taste and slowed digestion (Britton and McLaughlin, 2013).

Alterations in macronutrient composition may be the largest driving force behind differences in gut microbial communities, as evidenced by regional differences in dietary composition from an early age, leading to demonstrable differences in gut microbiota (Voreades et al., 2014). Long-term dietary intake, particularly protein and animal fat content vs. carbohydrate content, most strongly influence gut microbiome enterotype (Wu et al., 2011). However, short term dietary changes can also rapidly influence gut microbiome composition (Wu et al., 2011; David et al., 2014). More extreme examples of altered dietary patterns, such as ketogenic (Newell et al., 2016; Olson et al., 2018; Cabrera-Mulero et al., 2019) and vegetarian or vegan diets (Tomova et al., 2019) also dramatically shift microbial composition. This is particularly relevant in the context of AD and related dementias, as both Mediterranean and ketogenic diets have been utilized in pre-clinical and clinical studies with promising results in regards to improving cognitive deficits (Solfrizzi et al., 2011; Lourida et al., 2013; McDonald and Cervenka, 2018; Rusek et al., 2019).

Although dietary composition has a large influence on microbiome composition, altered dietary patterns may have a strong influence as well. Obese individuals who restrict calorie intake demonstrate an increase in Bacteroidetes, significantly improving their Bacteroidetes:Firmicutes ratio, regardless of whether this reduction was through from altered fat or carbohydrate intake (Ley et al., 2006). Furthermore, calorie restriction improved microbial gene richness and improved metabolic parameters (Cotillard et al., 2013; Le Chatelier et al., 2013). The introduction of time restricted feeding (i.e., eating exclusively during specific times of the day) not only improves metabolic health, but improves diversity within the gut microbiome (Zarrinpar et al., 2014; van der Merwe et al., 2020).

The RAS is also heavily influenced by diet. High-salt diets can suppress systemic RAS, lowering plasma renin, angiotensin II (AngII) and aldosterone levels (He and MacGregor, 2011; Charytan and Forman, 2012). Both obesity and starvation have profound effects on angiotensinogen, the precursor to AngII (Frederich et al., 1992; Turban et al., 2002). Obese prone rats demonstrate increased angiotensin-related gene expression following 8 weeks of a high fat diet relative to lean and obese resistant rats (Boustany et al., 2004). Obesity not only negatively influences hypertension and RAS signaling, but greatly increases the risk of dementia in aged individuals (Whitmer et al., 2005; Beydoun et al., 2008). Furthermore, individuals with dementias demonstrate altered eating patterns (Morris et al., 1989; Ikeda et al., 2002; Sandilyan, 2011), perhaps enhancing age-related gut dysbiosis. Of note, several...
subtypes of dementias correlated with a significant increase in preference for sweet foods (Ikeda et al., 2002), which can lead to detrimental shifts in carbohydrate intake.

Beyond the direct relationship of dietary consumption patterns and altered microbial diversity, diet can have a profound influence on central nervous system function in aged subjects through alterations in energy bioavailability (Hernandez and Burke, 2018; Mujica-Parodi et al., 2020). Probiotics and fermented foods may enhance the link between the gut and brain through increased GABA, serotonin and/or BDNF (Chung et al., 2014; Kim et al., 2016).

**Physical Exercise**

Physical exercise represents an important healthy aging intervention with important implications for brain health (Ahlskog et al., 2011; Buchman et al., 2012), and exercise directly modulates the gut microbiome (Mailing et al., 2019). The activity status of an organism also directly influences drug responsiveness due to differences in various hemodynamic and metabolic outcomes (Lenz et al., 2004; Lenz, 2011)—often demonstrating differing drug effects under active and sedentary states (Huffman et al., 2008; Narkar et al., 2008; Buford et al., 2012; Menzies et al., 2013). Therefore, it is possible that utilization of an Ang (1–7)-targeting GMP could be most effective when combined with physical exercise.

Exercise alone can alter the gut microbiome, as reviewed previously (Mailing et al., 2019). Specifically, exercise is able to increase the abundance of butyrate-producing taxa (Matsumoto et al., 2008; Evans et al., 2014; Kang et al., 2014). This may have interesting implications in aging individuals with or without dementia, as butyrate itself is anti-inflammatory, beneficial for metabolic health and can boost production of ketones to serve as a fuel source (Cavaleri and Bashar, 2018). This is particularly beneficial given the negative alterations in glucose utilization in aged dementia patients. However, the type of exercise may influence the gut microbiome in different ways (Allen et al., 2015) and there are conflicting data as to how certain phyla are altered in both preclinical animal models and human data (Mailing et al., 2019). However, a study utilizing the APP/PS1 transgenic mouse model of AD demonstrated significant advantage of both exercise and probiotic use (Abraham et al., 2019), strengthening the argument for physical activity and gut health in AD treatment.

Similarly, exercise can have drastic effects on the RAS. Chronic exercise not only improves systemic blood pressure, but prevents increased expression of ACE and AT1R in hypertensive rats—while simultaneously preventing a decrease in ACE2 and MasR expression normally observed in these animals (Agarwal et al., 2011). This study also showed that in addition to regulating the vasoconstrictor axis of the RAS, chronic exercise also attenuates inflammatory cytokine expression. Exercise training attenuates ROS within the paraventricular nucleus, a brain region involved in the RAS (Zhang et al., 2016). Additionally, exercise improves vascular sensitivity to insulin through the action of Ang (1–7) action at the MasR (Gallardo-Ortiz et al., 2020), which may be of particular relevance to individuals with insulin-related impairments including diabetes and AD.
An abundance of evidence demonstrates the potential for exercise to improve quality of life in advanced age (Mazzeo et al., 1998; Spirduso and Cronin, 2001; Rejeski et al., 2002; Courneya and Karvinen, 2007), as well as dementia (Ahlskog et al., 2011). Taken together, data from exercise studies suggest that combining a RAS-affecting GMP with physical exercise could have enhanced ability to target the multi-system decline often facing dementia patients.

**CONCLUDING REMARKS**

Alzheimer’s disease (AD) is one of the most prevalent age-related inflictions among the elderly population, but there are currently no available therapeutics of any kind capable of preventing or curing this disease state. One potential approach is through the gut, but significant work is required to determine how such interventions can be implemented and the degree to which they can be efficacious. Probiotic-based interventions may be a good choice, provided there is an appropriate vessel through which systemic alterations can be administered. Though there is limited clinical evidence for the effectiveness of probiotics in dementia, there is a strong link between gut microbiome and brain function/dysfunction, including distinct microbial profiles in major depressive disorder (Zheng et al., 2016), autism spectrum disorders (Krajmalnik-Brown et al., 2015), schizophrenia (Shen et al., 2018) and microbiome-dependent resistance to seizure activity (Olson et al., 2018).

Thus, as outlined in this review, the utilization of genetically-modified probiotics (GMPs) may hold promise for AD-related impairments via oral delivery of therapeutic compounds. Specifically, the utilization of GMPs from lactic acid bacteria which itself has inherent benefits and these GMPs can be further utilized to deliver compounds such as Angiotensin (1–7) as there is strong evidence for the role of the RAS in AD (Wright and Harding, 2010). We look forward to seeing the continued development of work in this space in effort to identify efficacious interventions to combat the ever-growing prevalence of AD and other forms of dementia in the rapidly aging population.

**FUNDING**

This work was supported by National Institute of Aging (R01AG054538 and P30 AG050886 to TB and CC), as well as the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health under Award Number T32HD071866.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article-supplementary material, further inquiries can be directed to the corresponding author(s).

**REFERENCES**

AbdAlla S, Langer A, Fu X, and Quitterer U (2013). ACE inhibition with captopril retards the development of signs of neurodegeneration in an animal model of Alzheimer’s disease. Int. J. Mol. Sci 14, 16917–16942. doi: 10.3390/ijms140816917 [PubMed: 23959119]

Abraham D, Feher J, Scuderi GL, Szabo D, Dobolyi A, Cservenak M, et al. (2019). Exercise and probiotics attenuate the development of Alzheimer’s disease in transgenic mice: role of microbiome. Exp. Gerontol 115, 122–131. doi: 10.1016/j.exger.2018.12.005 [PubMed: 30529024]
Agarwal D, Welsch MA, Keller JN, and Francis J (2011). Chronic exercise modulates RAS components and improves balance between pro- and anti-inflammatory cytokines in the brain of SHR. Basic Res. Cardiol 106, 1069–1085. doi: 10.1007/s00395-011-0231-7 [PubMed: 22124756]

Ahlsgog JE, Geda YE, Graff-Radford NR, and Petersen RC (2011). Physical exercise as a preventive or disease-modifying treatment of dementia and brain aging. Mayo Clin. Proc 86, 876–884. doi: 10.4065/mcp.2011.0252 [PubMed: 21878600]

Akbari E, Asemi Z, Daneshvar Kakhi R, Bahmani F, Kouchaki E, Tajmaji OR, et al. (2016). Effect of probiotic supplementation on cognitive function and metabolic status in Alzheimer’s disease: a randomized, double-blind and controlled trial. Front. Aging Neurosci 8:256. doi: 10.3389/fnagi.2016.00256 [PubMed: 27891089]

Alkasir R, Li J, Li X, Jin M, and Zhu B (2017). Human gut microbiota: the links with dementia development. Protein Cell 8, 90–102. doi: 10.1007/s13238-016-0338-6 [PubMed: 27866330]

Allen AM, MacGregor DP, Chai SY, Donnan GA, Kaczmarczyk S, Richardson K, et al. (1992). Angiotensin II receptor binding associated with nigrostriatal dopaminergic neurons in human basal ganglia. Ann. Neurol 32, 339–344. doi: 10.1002/ana.410320306 [PubMed: 1416803]

Allen JM, Berg Miller ME, Pence BD, Whitlock K, Nehra V, Gaskins HR, et al. (2015). Voluntary and forced exercise differentially alters the gut microbiome in C57BL/6j mice. J. Appl. Physiol 118, 1059–1066. doi: 10.1152/japplphysiol.01077.2014 [PubMed: 25678701]

Arora T, Singh S, and Sharma RK (2013). Probiotics: interaction with gut microbiome and antiobesity potential. Nutrition 29, 591–596. doi: 10.1016/j.nut.2012.07.017 [PubMed: 23287068]

Baldauf K, Royal J, Hamorsky K, and Matoba N (2015). Cholera toxin B: one subunit with many pharmaceutical applications. Toxins 7, 974–996. doi: 10.3390/toxins7030974 [PubMed: 25802972]

Barra M, Danino T, and Garrido D (2020). Engineered probiotics for detection and treatment of inflammatory intestinal diseases. Front. Bioeng. Biotechnol 8:265. doi: 10.3389/fbioe.2020.00265 [PubMed: 32296696]

Barron AM, and Pike CJ (2012). Sex hormones, aging, and Alzheimer’s disease. Front. Biosci 4, 976–997. doi: 10.2741/e434

Bäuerl C, Collado MC, Cuevas AD, Viña J, and Martínez GP (2018). Shifts in gut microbiota composition in an APP/PSS1 transgenic mouse model of Alzheimer’s disease during lifespan. Lett. Appl. Microbiol 66, 464–471. doi: 10.1111/lam.12882 [PubMed: 29575030]

Becker LK, Etelvino GM, Walther T, Santos RAS, and Campagnole- Santos MJ (2007). Immunofluorescence localization of the receptor Mas in cardiovascular-related areas of the rat brain. Am. J. Physiol. Heart Circ. Physiol 293, H1416–1424. doi: 10.1152/ajpheart.00141.2007 [PubMed: 17496218]

Belkaid Y, and Naik S (2013). Compartmentalized and systemic control of tissue immunity by commensals. Nat. Immunol 14, 646–653. doi: 10.1038/ni.2604 [PubMed: 23778971]

Berer K, Mues M, Koutrolos M, Rasbi ZA, Boziki M, Johner C, et al. (2011). Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature 479, 538–541. doi: 10.1038/nature10554 [PubMed: 22031325]

Bermúdez-Humarán LG, Aubry C, Motta J-P, Deraison C, Steidler L, Vergnolle N, et al. (2013). Engineering lactococci and lactobacilli for human health. Curr. Opin. Microbiol 16, 278–283. doi: 10.1016/j.mib.2013.06.002 [PubMed: 23880097]

Beydoun MA, Beydoun HA, and Wang Y (2008). Obesity and central obesity as risk factors for incident dementia and its subtypes: a systematic review and meta-analysis. Obes. Rev 9, 204–218. doi: 10.1111/j.1467-789X.2008.00473.x [PubMed: 18331422]

Börnö RA, Kandasamy V, Axelsen AM, Nielsen AT, and Bosma EF (2019). Genome editing of lactic acid bacteria: opportunities for food, feed, pharma and biotech. FEMS Microbiol. Lett 366, fny291. doi: 10.1093/femsle/fny291

Boustany CM, Bharadwaj K, Daugherty A, Brown DR, Randall DC, and Cassis LA (2004). Activation of the systemic and adipose renin-angiotensin system in rats with diet-induced obesity and hypertension. Am. J. Physiol. Regul. Integrat. Comparat. Physiol 287, R943–R949. doi: 10.1152/ajpregu.00265.2004

Front Aging. Author manuscript; available in PMC 2021 December 10.
Boyle PA, Wilson RS, Aggarwal NT, Tang Y, and Bennett DA (2006). Mild cognitive impairment: risk of Alzheimer disease and rate of cognitive decline. Neurology 67, 441–445. doi: 10.1212/01.wnl.0000228244.10416.20 [PubMed: 16894105]

Brandscheid C, Schuck F, Reinhardt S, Schäfer K-H, Pietrzik CU, Grimm M, et al. (2017). Altered gut microbiome composition and tryptic activity of the 5xFAD Alzheimer’s mouse model. J. Alzheimer Dis 56, 775–788. doi: 10.3233/JAD-160926

Bravo JA, Forsythe P, Chew MV, Escaravage E, Savignac HM, Dinan TG, et al. (2011). Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc. Natl. Acad. Sci. U.S.A 108, 16050–16055. doi: 10.1073/pnas.1102999108 [PubMed: 21876150]

Britton E, and McLaughlin JT (2013). Ageing and the gut. Proc. Nutr. Soc 72, 173–177. doi: 10.1017/S0029665112002807 [PubMed: 23146206]

Bruzzese E, Callegari ML, Raia V, Visco S, Scotto R, Ferrari S, et al. (2014). Disrupted intestinal microbiota and intestinal inflammation in children with cystic fibrosis and its restoration with lactobacillus GG: a randomised clinical trial. PLoS ONE 9:e87796. doi: 10.1371/journal.pone.0087796 [PubMed: 24586292]

Buchman AS, Boyle PA, Yu L, Shah RC, Wilson RS, and Bennett DA (2012). Total daily physical activity and the risk of AD and cognitive decline in older adults. Neurology 78, 1323–1329. doi: 10.1212/WNL.0b013e3182535d35 [PubMed: 22517108]

Buford TW (2017). (Dis)Trust your gut: the gut microbiome in age-related inflammation, health, and disease. Microbiome 5:80. doi: 10.1186/s40168-017-0296-0 [PubMed: 28709450]

Buford TW, Manini TM, Hsu F-C, Cesari M, Anton SD, Nayfield S, et al. (2012). Angiotensin-converting enzyme inhibitor use by older adults is associated with greater functional responses to exercise. J. Am. Geriatr. Soc 60, 1244–1252. doi: 10.1111/j.1532-5415.2012.04045.x [PubMed: 22726232]

Buford TW, Sun Y, Roberts LM, Banerjee A, Peramsetty S, Knighton A, et al. (2020). Angiotensin (1–7) delivered orally via probiotic, but not subcutaneously, benefits the gut-brain axis in older rats. GeroScience 42, 1307–1321. doi: 10.1007/s11357-020-00196-y [PubMed: 32451847]

Cabrera-Mulero A, Tinahones A, Bandera B, Moreno-Indias I, Macías-González M, and Tinahones FJ (2019). Keto microbiota: a powerful contributor to host disease recovery. Rev. Endocr. Metab. Disord 20, 415–425. doi: 10.1007/s11154-019-09518-8 [PubMed: 31720986]

Cano-Garrido O, Seras-Franzoso J, and Garcia-Fruitós E (2015). Lactic acid bacteria: reviewing the potential of a promising delivery live vector for biomedical purposes. Microb. Cell Fact 14:137. doi: 10.1186/s12934-015-0313-6 [PubMed: 26377321]

Carrillo MC, and Vellas B (2013). New and different approaches needed for the design and execution of Alzheimer’s clinical trials. Alzheimers. Dement 9, 436–437. doi: 10.1016/j.jalz.2013.03.008 [PubMed: 23809363]

Carter CS, Morgan D, Verma A, Lobaton G, Aquino V, Summers E, et al. (2019). Therapeutic delivery of Ang(1–7) via genetically modified probiotic: a dosing study. J. Gerontol. A Biol. Sci. Med. Sci 75, 1299–1303. doi: 10.1093/gerona/glz222

Cassani E, Privitera G, Pezzoli G, Pusani C, Madio C, Iorio L, et al. (2011). Use of probiotics for the treatment of constipation in Parkinson’s disease patients. Minerva Gastroenterol. Dietol 57, 117–121. [PubMed: 21587143]

Cattaneo A, Cattane N, Galluzzi S, Provasi S, Lopizzo N, Festari C, et al. (2017). Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly. Neurobiol. Aging 49, 60–68. doi: 10.1016/j.neurobiolaging.2016.08.019 [PubMed: 27776263]

Cavaleri F, and Bashar E (2018). Potential synergies of β-hydroxybutyrate and butyrate on the modulation of metabolism, inflammation, cognition, and general health. J. Nutr. Metab 2018:87195760. doi: 10.1155/2018/87195760

Charytan DM, and Forman JP (2012). You are what you eat: dietary salt intake and renin angiotensin blockade in diabetic nephropathy. Kidney Int. 82, 257–259. doi: 10.1038/ki.2012.148 [PubMed: 22791321]
Chen Y, Fang L, Chen S, Zhou H, Fan Y, Lin L, et al. (2020). Gut microbiome alterations precede cerebral amyloidosis and microglial pathology in a mouse model of Alzheimer’s disease. BioMed Res. Int 2020:1–15. doi: 10.1155/2020/8456596

Chung Y-C, Jin H-M, Cui Y, Kim DS, Jung JM, Park J-I, et al. (2014). Fermented milk of Lactobacillus helveticus IDCC3801 improves cognitive functioning during cognitive fatigue tests in healthy older adults. J. Funct. Foods 10, 465–474. doi: 10.1016/j.jff.2014.07.007

Cohen LJ, Esterhayz D, Kim S-H, Lemetre C, Aguilar RR, Gordon EA, et al. (2017). Commensal bacteria make GPCR ligands that mimic human signalling molecules. Nature 549, 48–53. doi: 10.1038/nature23874 [PubMed: 2885168]

Cole-Jeffrey CT, Liu M, Katovich MJ, Raizada MK, and Shenoy V (2015). ACE2 and microbiota: emerging targets for cardiopulmonary disease therapy. J. Cardiovasc. Pharmacol 66, 540–550. doi: 10.1097/FJC.0000000000000307 [PubMed: 26322922]

Collins SM, Surette M, and Bercik P (2012). The interplay between the intestinal microbiota and the brain. Nat. Rev. Microbiol 10, 735–742. doi: 10.1038/nrmicro2876 [PubMed: 2300955]

Cotillard A, Kennedy SP, Kong LC, Prifti E, Pons N, Le Chatelier E, et al. (2013). Dietary intervention impact on gut microbial gene richness. Nature 500, 585–588. doi: 10.1038/nature12480 [PubMed: 23985875]

Courneya KS, and Karvinen KH (2007). Exercise, aging, and cancer. Appl. Physiol. Nutr. Metab 32, 1001–1007. doi: 10.1139/H07-074 [PubMed: 18059572]

David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, et al. (2014). Diet rapidly and reproducibly alters the human gut microbiome. Nature 505, 559–563. doi: 10.1038/ nature12820 [PubMed: 24336217]

de la Monte SM, and Wands JR (2008). Alzheimer’s Disease is type 3 diabetes--evidence reviewed. J. Diabetes Sci. Technol 2, 1101–1113. doi: 10.1177/193229680800200619 [PubMed: 19885299]

de la Torre JC (2004). Is Alzheimer’s disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol. 3, 184–190. doi: 10.1016/S1474-4422(04)00683-0 [PubMed: 14980533]

Dong Y-F, Kataoka K, Tokutomi Y, Nako H, Nakamura T, Toyama K, et al. (2011). Perindopril, a centrally active angiotensin-converting enzyme inhibitor, prevents cognitive impairment in mouse models of Alzheimer’s disease. FASEB J. 25, 2911–2920. doi: 10.1096/fj.11-182873 [PubMed: 21593435]

Doobay MF, Talman LS, Obr TD, Tian X, Davison RL, and Lazariguens E (2007). Differential expression of neuronal ACE2 in transgenic mice with overexpression of the brain renin-angiotensin system. Am. J. Physiol. Regul. Integr. Comp. Physiol 292, R373–381. doi: 10.1152/ajpregu.00292.2006 [PubMed: 16946085]

Durrer KE, Allen MS, and Hunt von Herbing I (2017). Genetically engineered probiotic for the treatment of phenylketonuria (PKU); assessment of a novel treatment in vitro and in the PAHenu2 mouse model of PKU. PLoS ONE 12:e0176286. doi: 10.1371/journal.pone.0176286 [PubMed: 28520731]

Evans CC, LePard KJ, Kwak JW, Stancukas MC, Laskowski S, Dougherty J, et al. (2014). Exercise prevents weight gain and alters the gut microbiota in a mouse model of high fat diet-induced obesity. PLoS ONE 9:e92193. doi: 10.1371/journal.pone.0092193 [PubMed: 24670791]

Favre GA, Esnault VLM, and Van Obbergen E (2015). Modulation of glucose metabolism by the renin-angiotensin-aldosterone system. Am. J. Physiol. Endocrinol. Metab 308, E435–E449. doi: 10.1152/ajpendo.00391.2014 [PubMed: 25564475]

Federal Interagency Forum on Aging-Related Statistics (2006). Data Sources on Older Americans 2006. Washington, DC: U.S. Government Printing Office.

Fernández-Atucha A, Izaigire A, Fraile-Bermúdez AB, Kortajarena M, Larrinaga G, Martinez-Lage P, et al. (2017). Sex differences in the aging pattern of renin–angiotensin system serum peptidases. Biol. Sex Differ 8:5. doi: 10.1186/s13293-017-0128-8 [PubMed: 28174624]

Ferrington L, Miners JS, Palmer LE, Bond SM, Povey JE, Kelly PA, et al. (2011). Angiotensin II-inhibiting drugs have no effect on intraneuronal Aβ or oligomeric Aβ levels in a triple transgenic mouse model of Alzheimer’s disease. Am. J. Transl. Res 3, 197–208. [PubMed: 21416061]
Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, and van Goor H (2004). Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol 203, 631–637. doi: 10.1002/path.1570 [PubMed: 15141377]

Hampton T (2017). Organoids reveal clues to gut-brain communication. JAMA 318, 787–788. doi: 10.1001/jama.2017.11545 [PubMed: 28873141]

Harach T, Marungruang N, Duthilleul N, Cheatham V, Mc Coy KD, Frisoni G, et al. (2017). Reduction of Abeta amyloid pathology in APPPS1 transgenic mice in the absence of gut microbiota. Sci. Rep 7:41802. doi: 10.1038/srep41802 [PubMed: 28176819]

Harmer D, Gilbert M, Borman R, and Clark KL (2002). Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme. FEBS Lett. 532, 107–110. doi: 10.1016/S0014-5793(02)03640-2 [PubMed: 12459472]

Hashimoto T, Perlot T, Rehman A, Trichereau J, Ishiguro H, Paolino M, et al. (2012). ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature 487, 477–481. doi: 10.1038/nature11228 [PubMed: 22837003]

Hay M, Pelt R, Heien ML, Vanderah TW, Largent-Milnes TM, Rodgers K, et al. (2019). A novel angiotensin-(1–7) glycosylated mas receptor agonist for treating vascular cognitive impairment and inflammation-related memory dysfunction. J. Pharmacol. Exp. Ther 369, 9–25. doi: 10.1124/jpet.118.254854 [PubMed: 30709867]

Hay M, Vanderah TW, Samareh-Jahani F, Constantopoulos E, Uprety AR, Barnes CA, et al. (2017). Cognitive impairment in heart failure: a protective role for angiotensin-(1–7). Behav. Neurosci 131, 99–114. doi: 10.1037/bne0000182 [PubMed: 28054808]

He FJ, and MacGregor GA (2011). Salt reduction lowers cardiovascular risk: meta-analysis of outcome trials. Lancet 378, 380–382. doi: 10.1016/S0140-6736(11)61174-4 [PubMed: 21803192]

Henriksen EJ (2007). Improvement of insulin sensitivity by antagonism of the renin-angiotensin system. Am. J. Physiol. Regul. Integr. Comp. Physiol 293, R974–R980. doi: 10.1152/ajpregu.00147.2007 [PubMed: 17581838]

Hernandez AR, and Burke SN (2018). Age-related changes in “hub” neurons. Aging 10, 2551–2552. doi: 10.18632/aging.101606 [PubMed: 30348907]

Honda K, and Littman DR (2012). The microbiome in infectious disease and inflammation. Annu. Rev. Immunol 30, 759–795. doi: 10.1146/annurev-immunol-020711-074937 [PubMed: 22224764]

Hu X, Wang T, and Jin F (2016). Alzheimer’s disease and gut microbiota. Sci. China Life Sci 59, 1006–1023. doi: 10.1007/s11427-016-5083-9 [PubMed: 27566465]

Hu Z, Wang L, Ma S, Kirisci L, Feng Z, Xue Y, et al. (2018). Synergism of antihypertensives and cholinesterase inhibitors in Alzheimer’s disease. Alzheimer Dement. 4, 542–555. doi: 10.1016/j.tare.2018.09.001

Huffman KM, Slentz CA, Johnson JL, Samsa GP, Duscha BD, Tanner CJ, et al. (2008). Impact of hormone replacement therapy on exercise training-induced improvements in insulin action in sedentary overweight adults. Metab. Clin. Exp 57, 888–895. doi: 10.1016/j.metabol.2008.01.034 [PubMed: 18555828]

Hurd MD, Martorell P, Delavande A, Mullen KJ, and Langa KM (2013). Monetary costs of dementia in the United States. N. Engl. J. Med 368, 1326–1334. doi: 10.1056/NEJMc1204629 [PubMed: 23550670]

Hüttenrauch M, Baches S, Gerth J, Bayer TA, Weggen S, and Wirths O (2015). Neprilysin deficiency alters the neuropathological and behavioral phenotype in the 5XFAD mouse model of Alzheimer’s disease. J. Alzheimer. Dis 44, 1291–1302. doi: 10.3233/JAD-142463

Ikeda M, Brown J, Holland A, Fukuhara R, and Hodges J (2002). Changes in appetite, food preference, and eating habits in frontotemporal dementia and Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatry 73, 371–376. doi: 10.1136/jnnp.73.4.371 [PubMed: 12235302]

Insel TR, Landis SC, and Collins FS (2013). The NIH BRAIN initiative. Science 340, 687–688. doi: 10.1126/science.1239276 [PubMed: 23661744]

Jagust W (2001). Untangling vascular dementia. Lancet 358, 2097–2098. doi: 10.1016/S0140-6736(01)07230-0 [PubMed: 11784618]
Janson J, Laedtke T, Parisi JE, O’Brien P, Petersen RC, and Butler PC (2004). Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 53, 474–481. doi: 10.2337/diabetes.53.2.474 [PubMed: 14747300]

Jiang T, Tan L, Gao Q, Lu H, Zhu X-C, Zhou J-S, et al. (2016). Plasma angiotensin-(1–7) is a potential biomarker for Alzheimer’s disease. Curr. Neurovasc. Res 13, 96–99. doi: 10.2174/1567202613666160224124739 [PubMed: 26907614]

Jiang T, Yu J-T, Zhu X-C, Zhang Q-Q, Tan M-S, Cao L, et al. (2014). Angiotensin-(1–7) induces cerebral ischaemic tolerance by promoting brain angiogenesis in a Mas/eNOS-dependent pathway. Br. J. Pharmacol 171, 4222–4232. doi: 10.1111/bph.12770 [PubMed: 24824997]

Jin W-S, Bu X-L, Wang Y-R, Li L, Li W-W, Liu Y-H, et al. (2017). Reduced cardiovascular functions in patients with Alzheimer’s disease. J. Alzheimers. Dis 58, 919–925. doi: 10.3233/JAD-170088 [PubMed: 28505975]

Kamel AS, Abdelkader NF, Abd El-Rahman SS, Emara M, Zaki HF, and Khattab MM (2018). Stimulation of ACE2/ANG(1–7)/Mas axis by diminazene ameliorates Alzheimer’s disease in the D-galactose-ovariectomized rat model: role of PI3K/Akt pathway. Mol. Neurobiol 55, 8188–8202. doi: 10.1007/s12055-018-0966-3 [PubMed: 29516284]

Kang SS, Jeraldo PR, Kurti A, Miller MEB, Cook MD, Whitlock K, et al. (2014). Diet and exercise orthogonally alter the gut microbiome and reveal independent associations with anxiety and cognition. Mol. Neurodegener 9:36. doi: 10.1186/1750-1326-9-36 [PubMed: 25217888]

Kangussu LM, Almeida-Santos AF, Moreira FA, Fontes MAP, Santos RAS, Aguiar DC, et al. (2017). Reduced anxiety-like behavior in transgenic rats with chronically overproduction of angiotensin-(1–7): role of the mas receptor. Behav. Brain Res 331, 193–198. doi: 10.1016/j.bbr.2017.05.026 [PubMed: 28502733]

Kehoe PG (2018). The coming of age of the angiotensin hypothesis in Alzheimer’s disease: progress toward disease prevention and treatment? J. Alzheimers Dis 62, 1443–1466. doi: 10.3233/JAD-171119 [PubMed: 29562545]

Kehoe PG, Wong S, Al Mulhim N, Palmer LE, and Miners JS (2016). Angiotensin-converting enzyme 2 is reduced in Alzheimer’s disease in association with increasing amyloid-β and tau pathology. Alzheimers. Res. Ther 8, 50. doi: 10.1186/s13195-016-0217-7 [PubMed: 27884212]

Kennedy PJ, Cryan JF, Dinan TG, and Clarke G (2017). Kynurenine pathway metabolism and the microbiota-gut-brain axis. Neuropharmacology 112, 399–412. doi: 10.1016/j.neuropharm.2016.07.002 [PubMed: 27392632]

Kim B, Hong VM, Yang J, Hyun H, Im JJ, Hwang J, et al. (2016). A review of fermented foods with beneficial effects on brain and cognitive function. Prev. Nutr. Food Sci 21, 297–309. doi: 10.3746/pnf.2016.21.4.297 [PubMed: 28078251]

Kim W-K, Jang YJ, Seo B, Han DH, Park S, and Ko G (2019). Administration of Lactobacillus paracasei strains improves immunomodulation and changes the composition of gut microbiota leading to improvement of colitis in mice. J. Funct. Foods 52, 565–575. doi: 10.1016/j.jff.2018.11.035

Kouyama R, Suganami T, Nishida J, Tanaka M, Toyoda T, Kiso M, et al. (2005). Attenuation of diet-induced weight gain and adiposity through increased energy expenditure in mice lacking angiotensin II type 1a receptor. Endocrinology 146, 3481–3489. doi: 10.1210/en.2005-0003 [PubMed: 15878965]

Krajmalnik-Brown R, Lozupone C, Kang D-W, and Adams JB (2015). Gut bacteria in children with autism spectrum disorders: challenges and promise of studying how a complex community influences a complex disease. Microb. Ecol. Health Dis 26:26914. doi: 10.3402/mehd.v26.26914 [PubMed: 25769266]

Kumar DKV, Choi SH, Washicosky KJ, Eimer WA, Tucker S, Ghofrani J, et al. (2016). Amyloid-β peptide protects against microbial infection in mouse and worm models of Alzheimer’s disease. Sci. Transl. Med 8:340ra72. doi: 10.1126/scitranslmed.aaf1059

Kumar M, Yadav AK, Verma V, Singh B, Mal G, Nagpal R, et al. (2016). Bioengineered probiotics as a new hope for health and diseases: an overview of potential and prospects. Fut. Microbiol 11, 585–600. doi: 10.2217/fmb.16.4
Labandeira-Garcia JL, Rodriguez-Perez AI, Valenzuela R, Costa-Besada MA, and Guerra MJ (2016). Menopause and Parkinson’s disease. Interaction between estrogens and brain renin-angiotensin system in dopaminergic degeneration. Front. Neuroendocrinol 43, 44–59. doi: 10.1016/j.yfrne.2016.09.003 [PubMed: 27693730]

Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, et al. (2013). Richness of human gut microbiome correlates with metabolic markers. Nature 500, 541–546. doi: 10.1038/nature12506 [PubMed: 23985870]

LeBlanc JG, Aubry C, Cortes-Perez NG, de Moreno de LeBlanc A, Vergnolle N, Languella P, et al. (2013). Mucosal targeting of therapeutic molecules using genetically modified lactic acid bacteria: an update. FEMS Microbiol. Lett 344, 1–9. doi: 10.1111/1349-292X.12434

Leblhuber F, Steiner K, Schuetz B, Fuchs D, and Gostner JM (2018). Probiotic supplementation in patients with alzheimer’s dementia - an explorative intervention study. Curr. Alzheimer Res 15, 1106–1113. doi: 10.2174/1389200219666180813144834 [PubMed: 30101706]

Lenz TL (2011). The effects of high physical activity on pharmacokinetic drug interactions. Expert Opin. Drug Metab. Toxicol 7, 257–266. doi: 10.1517/17425255.2011.553190 [PubMed: 21244343]

Ley RE, Turnbaugh PJ, Klein S, and Gordon JI (2006). Human gut microbes associated with obesity. Nature 444, 1022–1023. doi: 10.1038/4441022a [PubMed: 17183309]

Li N-C, Lee A, Whitmer RA, Kivipelto M, Lawler E, Kazis LE, et al. (2010). Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BJM 340, b5465. doi: 10.1136/bmj.b5465 [PubMed: 20668258]

Liu P, Wu L, Peng G, Han Y, Tang R, Ge J, et al. (2019). Altered microbiomes distinguish Alzheimer’s disease from amnestic mild cognitive impairment and health in a Chinese cohort. Brain Behav. Immun 80, 633–643. doi: 10.1016/j.bbi.2019.05.008 [PubMed: 31063846]

Lönnemark E, Lappas G, Friman V, Wold AE, Backhaus E, and Adlerberth I (2015). Effects of probiotic intake and gender on nontyphoid salmonella infection. J. Clin. Gastroenterol 49, 116–123. doi: 10.1097/MCG.0000000000000120 [PubMed: 24667592]

Lourida I, Soni M, Thompson-Coon J, Purandare N, Lang IA, Ukoumunne OC, et al. (2013). Mediterranean diet, cognitive function, and dementia: a systematic review. Epidemiology 24, 479–489. doi: 10.1097/EDE.0b013e3182944410 [PubMed: 23680940]

Mailing LJ, Allen JM, Buford TW, Fields CJ, and Woods JA (2019). Exercise and the gut microbiome: a review of the evidence, potential mechanisms, and implications for human health. Exerc. Sport Sci. Rev 47, 75–85. doi: 10.1249/JES.0000000000000183 [PubMed: 30883471]

Marras C, Beck JC, Bower JH, Roberts E, Ritz B, Ross GW, et al. (2018). Prevalence of Parkinson’s disease across North America. NPJ Parkinson’s Dis. 4, 1–7. doi: 10.1038/s41531-018-0058-0 [PubMed: 29354683]

Martin F-PJ, Wang Y, Sprenger N, Yap IKS, Lundstedt T, Lek P, et al. (2008). Probiotic modulation of symbiotic gut microbiota–host metabolic interactions in a humanized microbiome mouse model. Mol. Syst. Biol 4:157. doi: 10.1038/molsb4100190 [PubMed: 18197175]

Matsumoto M, Inoue R, Tsukahara T, Ushida K, Chiji H, Matsubara N, et al. (2008). Voluntary running exercise alters microbiota composition and increases n-butyrate concentration in the rat cecum. Biosci. Biotechnol. Biochem 72, 572–576. doi: 10.1271/bbb.70474 [PubMed: 18256465]

Mazzeo RS, Cavanagh P, Evans WJ, Fiatarone M, Hagberg J, McAuley E, et al. (1998). ACSM position stand: exercise and physical activity for older adults. Med. Sci. Sports Exerc 30, 992–1008. doi: 10.1097/00005768-199806000-00033 [PubMed: 9624662]

McCabe LR, Irwin R, Schaefer L, and Britton RA (2013). Probiotic use decreases intestinal inflammation and increases bone density in healthy male but not female mice. J. Cell. Physiol 228, 1793–1798. doi: 10.1002/jcp.24340 [PubMed: 23389860]

McDonald TJW, and Cervenka MC (2018). Ketogenic diets for adult neurological disorders. Neurotherapeutics 15, 1018–1031. doi: 10.1007/s13311-018-0666-8 [PubMed: 30225789]
Menzies KJ, Singh K, Saleem A, and Hood DA (2013). Sirtuin 1-mediated effects of exercise and resveratrol on mitochondrial biogenesis. J. Biol. Chem 288, 6968–6979. doi: 10.1074/jbc.M112.431155 [PubMed: 23329826]

Miner-Williams WM, Stevens BR, and Moughan PJ (2014). Are intact peptides absorbed from the healthy gut in the adult human? Nutr. Res. Rev 27, 308–329. doi: 10.1017/S0954422414000225 [PubMed: 25623084]

Minter MR, Hinterleitner R, Meisel M, Zhang C, Leone V, Zhang X, et al. (2017). Antibiotic-induced perturbations in microbial diversity during post-natal development alters amyloid pathology in an aged APPSWE/PS1ΔE9 murine model of Alzheimer’s disease. Sci. Rep 7:10411. doi: 10.1038/s41598-017-11047-w [PubMed: 28874832]

Minter MR, Zhang C, Leone V, Ringus DL, Zhang X, Oyler-Castrillo P, et al. (2016). Antibiotic-induced perturbations in gut microbial diversity influences neuro-inflammation and amyloidosis in a murine model of Alzheimer’s disease. Sci. Rep 6:30028. doi: 10.1038/srep30028 [PubMed: 27443609]

Mogi M, Li J-M, Tsukuda K, Iwanami J, Min L-J, Sakata A, et al. (2008). Telmisartan prevented cognitive decline partly due to PPAR-γ activation. Biochem. Biophys. Res. Commun 375, 446–449. doi: 10.1016/j.bbrc.2008.08.032 [PubMed: 18715543]

Morris CH, Hope RA, and Fairburn CG (1989). Eating habits in dementia: a descriptive study. Br. J. Psychiatry 154, 801–806. doi: 10.1192/bjp.154.6.801 [PubMed: 2597886]

Mujica-Parodi LR, Amgalan A, Sultan SF, Antal B, Sun X, Skiena S, et al. (2020). Diet modulates brain network stability, a biomarker for brain aging, in young adults. Proc Natl Acad Sci U.S.A 117, 6170–6177. doi: 10.1073/pnas.1913042117 [PubMed: 32127481]

Naito E, Yoshida Y, Makino K, Kounoshi Y, Kunihiro S, Takahashi R, et al. (2011). Beneficial effect of oral administration of Lactobacillus casei strain Shirota on insulin resistance in diet-induced obesity mice. J. Appl. Microbiol 110, 650–657. doi: 10.1111/j.1365-2672.2010.04922.x [PubMed: 21281408]

Narkar VA, Downes M, Yu RT, Embler E, Wang Y-X, Banayo E, et al. (2008). AMPK and PPARdelta agonists are exercise mimetics. Cell 134, 405–415. doi: 10.1016/j.cell.2008.06.051 [PubMed: 18674809]

Ndagijimana M, Laghi L, Vitali B, Placucci G, Brigid P, and Guerzoni ME (2009). Effect of a symbiotic food consumption on human gut metabolic profiles evaluated by 1H nuclear magnetic resonance spectroscopy. Int. J. Food Microbiol 134, 147–153. doi: 10.1016/j.ijfoodmicro.2009.04.016 [PubMed: 19446905]

Newell C, Bomhof MR, Reimer RA, Hittel DS, Rho JM, and Shearer J (2016). Ketogenic diet modifies the gut microbiota in a murine model of autism spectrum disorder. Mol. Autism 7:37. doi: 10.1186/s13229-016-0099-3 [PubMed: 27594980]

Nieuwdorp M, Gilijamse PW, Pai N, and Kaplan LM (2014). Role of the microbiome in energy regulation and metabolism. Gastroenterology 146, 1525–1533. doi: 10.1053/j.gastro.2014.02.008 [PubMed: 24560870]

O’Caoimh R, Healy L, Gao Y, Svendrovski A, Kerins DM, Eustace J, et al. (2014). Effects of centrally acting angiotensin converting enzyme inhibitors on functional decline in patients with Alzheimer’s disease. J. Alzheimer Dis 40, 595–603. doi: 10.3233/JAD-131694

Olson CA, Vuong HE, Yano JM, Liang QY, Nusbaum DJ, and Hsiao EY (2018). The gut microbiota mediates the anti-seizure effects of the ketogenic diet. Cell 173, 1728–1741.e13. doi: 10.1016/j.cell.2018.04.027 [PubMed: 29804833]

O’Mahony SM, Clarke G, Borre YE, Dinan TG, and Cryan JF (2015). Serotonin, tryptophan metabolism and the brain-gut-microbiome axis. Behav. Brain Res 277, 32–48. doi: 10.1016/j.bbr.2014.07.027 [PubMed: 25078296]

Ongali B, Nicolakakis N, Tong XK, Aboulkassim T, Papadopoulos P, Rosa-Neto P, et al. (2014). Angiotensin II type 1 receptor blocker losartan prevents and rescues cerebrovascular, neuropathological and cognitive deficits in an Alzheimer’s disease model. Neurobiol. Dis 68, 126–136. doi: 10.1016/j.nbd.2014.04.018 [PubMed: 24807206]

Passos-Silva DG, Verano-Braga T, and Santos RAS (2013). Angiotensin-(1–7): beyond the cardio-renal actions. Clin. Sci 124, 443–456. doi: 10.1042/CS20120461

Front Aging. Author manuscript; available in PMC 2021 December 10.
Paton AW, Morona R, and Paton JC (2012). Bioengineered microbes in disease therapy. Trends Mol. Med 18, 417–425. doi: 10.1016/j.molmed.2012.05.006 [PubMed: 22721939]

Perez-Pardo P, Kliest T, Dodiya HB, Broersen LM, Garssen J, Keshavarzian A, et al. (2017). The gut-brain axis in Parkinson’s disease: possibilities for food-based therapies. Eur. J. Pharmacol 817, 86–95. doi: 10.1016/j.ejphar.2017.05.042 [PubMed: 28549787]

Perlot T, and Penninger JM (2013). ACE2 - from the renin-angiotensin system to gut microbiota and malnutrition. Microbes Infect. 15, 866–873. doi: 10.1016/j.micinf.2013.08.003 [PubMed: 23962453]

Pistilliato F, Sumalla Cano S, Elio I, Masias Vergara M, Giampieri F, and Battino M (2016). Role of gut microbiota and nutrients in amyloid formation and pathogenesis of Alzheimer disease. Nutr. Rev 74, 624–634. doi: 10.1093/nutri/nwu023 [PubMed: 27634977]

Plavec TV, and Berlec A (2019). Engineering of lactic acid bacteria for delivery of therapeutic proteins and peptides. Appl. Microbiol. Biotechnol 103, 2053–2066. doi: 10.1007/s00253-019-09628-y [PubMed: 30656391]

Proctor C, Thiennimitr P, Chattipakorn N, and Chattipakorn SC (2017). Diet, gut microbiota and cognition. Metab. Brain Dis 32, 1–17. doi: 10.1007/s11011-016-9917-8 [PubMed: 27709426]

Quitterer U, and AbdAlla S (2020). Improvements of symptoms of Alzheimer’s disease by inhibition of the angiotensin system. Pharmacolet Res 154:104230. doi: 10.1016/j.phrs.2019.04.014 [PubMed: 30991105]

Ragonnaud E, and Biragyn A (2021). Gut microbiota as the key controllers of “healthy” aging of elderly people. Immun. Ageing 18:2. doi: 10.1186/s12979-020-00213-w [PubMed: 33397404]

Rajazda MK, Joe B, Bryan NS, Chang EB, Dewhirst FE, Borisy GG, et al. (2017). Report of the national heart, lung, and blood institute working group on the role of microbiota in blood pressure regulation: current status and future directions. Hypertension. doi: 10.1161/HYPERTENSIONAHA.117.09699. [Epub ahead of print].

Rasgon NL, Silverman D, Siddarth P, Miller K, Ercoli LM, Elman S, et al. (2005). Estrogen use and brain metabolic change in postmenopausal women. Neurobiol. Aging 26, 229–235. doi: 10.1016/j.neurobiolaging.2004.03.003 [PubMed: 15582750]

Reckelhoff Jane F, Zhang H, and Srivastava K (2000). Gender differences in development of hypertension in spontaneously hypertensive rats. Hypertension 35, 480–483. doi: 10.1161/01.HYP.35.1.480 [PubMed: 10642345]

Rejeski WJ, Focht BC, Messier SP, Morgan T, Pahor M, and Penninx B (2002). Obese, older adults with knee osteoarthritis: weight loss, exercise, and quality of life. Health Psychol. 21, 419–426. doi: 10.1037/0278-6133.21.5.419 [PubMed: 12211508]

Royea J, Zhang L, Tong X-K, and Hamel E (2017). Angiotensin IV receptors mediate the cognitive and cerebrovascular benefits of losartan in a mouse model of Alzheimer’s disease. J. Neurosci 37, 5562–5573. doi: 10.1523/JNEUROSCI.0329-17.2017 [PubMed: 28476949]

Rusek M, Pluta R, Ulamek-Kozioł M, and Czuczwar SJ (2019). Ketogenic diet in Alzheimer’s disease. Int. J. Mol. Sci 20:3892. doi: 10.3390/ijms20163892

Sakakibara R, Odaka T, Uchiyama T, Asahina M, Yamaguchi K, Yamaguchi T, et al. (2003). Colonic transit time and rectoanal videomanometry in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 74, 268–272. doi: 10.1136/jnnp.74.2.268 [PubMed: 12531969]

Sampson TR, Debelius JW, Thron T, Janssen S, Shastri GG, Ilhan ZE, et al. (2016). Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease. Cell 167, 1469–1480.e12. doi: 10.1016/j.cell.2016.11.018 [PubMed: 27912057]

Sandilyan MB (2011). Abnormal eating patterns in dementia- a cause for concern. Age Ageing 40. doi: 10.1093/ageing/el_195

Schmidt R, Schmidt H, Curb JD, Masaki K, White LR, and Launer LJ (2002). Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia aging study. Ann. Neurol 52, 168–174. doi: 10.1002/ana.10265 [PubMed: 12210786]

Schwiertz A, Spiegel J, Dillmann U, Grundmann D, Bürmann J, Fußbender K, et al. (2018). Fecal markers of intestinal inflammation and intestinal permeability are elevated in Parkinson’s disease. Parkinsonism Relat. Disord 50, 104–107. doi: 10.1016/j.parkreldis.2018.02.022 [PubMed: 29454662]
Selkoe DJ (2001). Alzheimer’s disease: genes, proteins, and therapy. Physiol. Rev 81, 741–766. doi: 10.1152/physrev.2001.81.2.741 [PubMed: 11274343]

Sharon G, Sampson TR, Geschwind DH, and Mazmanian SK (2016). The central nervous system and the gut microbiome. Cell 167, 915–932. doi: 10.1016/j.cell.2016.10.027 [PubMed: 27814521]

Shen L, Liu L, and Ji H-F (2017). Alzheimer’s disease histological and behavioral manifestations in transgenic mice correlate with specific gut microbiome state. J. Alzheim. Dis 56, 385–390. doi: 10.3233/JAD-160884

Shen Y, Xu J, Li Z, Huang Y, Yuan Y, Wang J, et al. (2018). Analysis of gut microbiota diversity and auxiliary diagnosis as a biomarker in patients with schizophrenia: a cross-sectional study. Schizophr. Res 197, 470–477. doi: 10.1016/j.schres.2018.01.002 [PubMed: 29352709]

Shigemori S, and Shimosato T (2017). Applications of genetically modified immunobiotics with high immunoregulatory capacity for treatment of inflammatory bowel diseases. Front. Immunol 8:22. doi: 10.3389/fimmu.2017.00022 [PubMed: 28179904]

Sica D (2011). Are there pleiotropic effects of antihypertensive medications or is it all about the blood pressure in the patient with diabetes and hypertension? J. Clin. Hypertens 13, 301–304. doi: 10.1111/j.1751-7176.2011.00450.x

Simon CB, Lee-McMullen B, Phelan D, Gilkes J, Carter CS, and Buford TW (2015). The renin–angiotensin system and prevention of age-related functional decline: where are we now? Age 37:9753. doi: 10.1007/s11357-015-9753-5 [PubMed: 25663422]

Singer D, Camargo SMR, Ramadan T, Schäfer M, Mariotta L, Herzog B, et al. (2012). Defective intestinal amino acid absorption in Ace2 null mice. Am. J. Physiol. Gastrointest. Liver Physiol 303, G686–695. doi: 10.1152/ajpgi.00140.2012 [PubMed: 22790597]

Solfrizzi V, Frisardi V, Seripa D, Logroscino GP, Imbimbo B, D’Onofrio G, et al. (2011). Mediterranean diet in predementia and dementia syndromes. Curr. Alzheimer. Res 8, 520–542. doi: 10.2174/156720511796391809 [PubMed: 21605047]

Soto ME, Abellan van Kan G, Nourhashemi F, Gillette-Guyonnet S, Cesari M, Cantet C, et al. (2013). Angiotensin-converting enzyme inhibitors and Alzheimer’s disease progression in older adults: results from the réseau sur la maladie d’alzheimer français cohort. J. Am. Geriatr. Soc 61, 1482–1488. doi: 10.1111/j.1469-8517.2013.00028.x

Spirduso WW, and Cronin DL (2001). Exercise dose-response effects on quality of life and independent living in older adults. Med. Sci. Sports Exerc 33 (6 Suppl), S598–608; discussion S609–610. doi: 10.1097/00005768-200106001-00028 [PubMed: 11427784]

Steidler L (2003). Genetically engineered probiotics. Best Pract. Res. Clin. Gastroenterol 7, 861–876. doi: 10.1016/S1521-6918(03)00072-6

Steidler L, Neiryck S, Huyghebaert N, Snoeck V, Vermeire A, Goddeeris B, et al. (2003). Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nat. Biotechnol 21, 785–789. doi: 10.1038/nbt840 [PubMed: 12808464]

Strandwitz P (2018). Neurotransmitter modulation by the gut microbiota. Brain Res. 1693, 128–133. doi: 10.1016/j.brainres.2018.03.015 [PubMed: 29903615]

Sullivan JC, Bhatia K, Yamamoto T, and Elmarakby AA (2010). Angiotensin (1–7) receptor antagonism equalizes angiotensin II-induced hypertension in male and female spontaneously hypertensive rats. Hypertension 56, 658–666. doi: 10.1161/HYPERTENSIONAHA.110.153668 [PubMed: 20713916]

Sun Y, Baptista LC, Roberts LM, Jumbo-Lucioni P, McMahon LL, Buford TW, et al. (2019). The gut microbiome as a therapeutic target for cognitive impairment. J Gerontol Series A 75, 1242–1250. doi: 10.1093/gerona/glz281

Syvanen M (2003). Churning out safer microbes for drug delivery. Nat. Biotechnol 21, 758–759. doi: 10.1038/nbt0703-758 [PubMed: 12833095]

Takeda S, Sato N, Takeuchi D, Kurinami H, Shinohara M, Niisato K, et al. (2009). Angiotensin receptor blocker prevented betaamyloid-induced cognitive impairment associated with recovery of neurovascular coupling. Hypertension. 54, 1345–1352. doi: 10.1161/ HYPERTENSIONAHA.109.138586 [PubMed: 19805638]

Tamtaji OR, Taghizadeh M, Daneshvar Kahkahi R, Kouchaki E, Bahmani F, Borzabadi S, et al. (2019). Clinical and metabolic response to probiotic administration in people with Parkinson’s
disease: a randomized, double-blind, placebo-controlled trial. Clin. Nutr 38, 1031–1035. doi: 10.1016/j.clnu.2018.05.018 [PubMed: 29891223]
Tan AH, Mahadeva S, Thalha AM, Gibson PR, Kiew CK, Yeat CM, et al. (2014). Small intestinal bacterial overgrowth in Parkinson’s disease. Parkinsonism Relat. Disord 20, 535–540. doi: 10.1016/j.parkreldis.2014.02.019 [PubMed: 24637123]
Tatchum-Talom R, Eyster KM, and Martin DS (2005). Sexual dimorphism in angiotensin II-induced hypertension and vascular alterations. Can. J. Physiol. Pharmacol 83, 413–422. doi: 10.1139/y05-012 [PubMed: 15897923]
Taylor CP, and Lamont JT (2005). Genetically engineered probiotics: a new twist on an old remedy. Gastroenterology 128, 1509–1512. doi: 10.1053/gastro.2005.03.052 [PubMed: 15887131]
Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, and Turner AJ (2000). A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J. Biol. Chem 275, 33238–33243. doi: 10.1074/jbc.M002615200 [PubMed: 10924499]
Tomova A, Bukovsky I, Rembert E, Yonas W, Alwarith J, Barnard ND, et al. (2019). The effects of vegetarian and vegan diets on gut microbiota. Front. Nutr 6:47. doi: 10.3389/fnut.2019.00047 [PubMed: 31058160]
Torika N, Asraf K, Apte RN, and Fleisher-Berkovich S (2018). Candesartan ameliorates brain inflammation associated with Alzheimer’s disease. CNS Neurosci. Ther 24, 231–242. doi: 10.1111/cns.12802 [PubMed: 29365370]
Torika N, Asraf K, Roasso E, Danon A, and Fleisher-Berkovich S (2016). Angiotensin converting enzyme inhibitors ameliorate brain inflammation associated with microglial activation: possible implications for Alzheimer’s disease. J. Neuroimmune Pharmacol 11, 774–785. doi: 10.1007/s11481-016-9703-8 [PubMed: 27562846]
Trigiani LJ, Royea J, Lacalle-Arioles M, Tong X-K, and Hamel E (2018). Pleiotropic benefits of the angiotensin receptor blocker candesartan in a mouse model of Alzheimer disease. Hypertension 72, 1217–1226. doi: 10.1161/HYPERTENSIONAHA.118.11775 [PubMed: 30354809]
Tsukuda K, Mogi M, Iwanami J, Min L-J, Sakata A, Jing F, et al. (2009). Cognitive deficit in amyloid-beta-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-gamma activation. Hypertension 54, 782–787. doi: 10.1161/HYPERTENSIONAHA.109.136879 [PubMed: 19635982]
Turbin S, Hainault I, Truccolo J, Andre J, Ferre P, Quignard-Boulange A, et al. (2002). Specific increase in leptin production in obese (falfa) rat adipose cells. Biochem. J 362, 113–118. doi: 10.1042/bj3620113 [PubMed: 11829746]
Turrel O, Goguel V, and Preat T (2017). Drosophila neprilysin 1 rescues memory deficits caused by amyloid-beta peptide. J. Neurosci 37, 10334–10345. doi: 10.1523/JNEUROSCI1634-17.2017 [PubMed: 28931572]
vander Merwe M, Sharma S, Caldwell JL, Smith NJ, Gomes CK, Bloomer RJ, et al. (2020). Time of feeding alters obesity-associated parameters and gut bacterial communities, but not fungal populations, in C57BL/6 male mice. Curr. Dev. Nutr 4:nzz145. doi: 10.1093/cdn/nzz145 [PubMed: 32025616]
Vemuri R, Sylvia KE, Klein SL, Forster SC, Plebanski M, Eri R, et al. (2019). The microgenderome revealed: sex differences in bidirectional interactions between the microbiota, hormones, immunity and disease susceptibility. Semin. Immunopathol 41, 265–275. doi: 10.1007/s00281-018-0716-7 [PubMed: 30298433]
Verma A, Xu K, Du T, Zhu P, Liang Z, Liao S, et al. (2019). Expression of human ACE2 in lactobacillus and beneficial effects in diabetic retinopathy in mice. Mol. Ther. Methods Clin. Dev 14, 161–170. doi: 10.1016/j.omtm.2019.06.007 [PubMed: 31380462]
Verma A, Zhu P, Xu K, Du T, Liao S, Liang Z, et al. (2020). Angiotensin-(1–7) expressed from lactobacillus bacteria protect diabetic retina in mice. Transl. Vis. Sci. Technol 9:20. doi: 10.1167/tvst.9.13.20
Vitali B, Ndagijimana M, Cruciani F, Carnevali P, Candela M, Guerzoni ME, et al. (2010). Impact of a symbiotic food on the gut microbial ecology and metabolic profiles. BMC Microbiol. 10:4. doi: 10.1186/1471-2180-10-4 [PubMed: 20055983]
Vogt NM, Kerby RL, Dill-McFarland KA, Harding SJ, Merluzzi AP, Johnson SC, et al. (2017). Gut microbiome alterations in Alzheimer’s disease. Sci. Rep 7:13537. doi: 10.1038/s41598-017-13601-y [PubMed: 29051531]

Voreades N, Kozil A, and Weir TL (2014). Diet and the development of the human intestinal microbiome. Front. Microbiol 5:494. doi: 10.3389/fmicb.2014.00494 [PubMed: 25295033]

Wang J, Ho L, Chen L, Zhao Z, Zhao W, Qian X, et al. (2007). Valsartan lowers brain β-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J. Clin. Invest 117, 3393–3402. doi: 10.1172/JCI31547 [PubMed: 17965777]

Wang S, Ahmadi S, Nagpal R, Jain S, Mishra SP, Kavanagh K, et al. (2020). Lipoteichoic acid from the cell wall of a heat killed Lactobacillus paracasei D3–5 ameliorates aging-related leaky gut, inflammation and improves physical and cognitive functions; from C. elegans to mice. GeroScience 42, 333–352. doi: 10.1007/s11357-019-00137-4 [PubMed: 31814084]

Wang X-L, Iwami J, Min L-J, Tsukuda K, Nakaoka H, Bai H-Y, et al. (2016). Deficiency of angiotensin-converting enzyme 2 causes deterioration of cognitive function. NPJ Aging Mech. Dis 2:16024. doi: 10.1038/njpaam.2016.24 [PubMed: 28721275]

Wei L, Jie-wen Z, Fen LU, Ming-ming MA, Jiang-qiao W, Ai-qin SUO, et al. (2012). Effects of telmisartan on the level of Aβ1–42, interleukin-1β, tumor necrosis factor α and cognition in hypertensive patients with Alzheimer’s disease. Natl. Med. J. China 92, 2743–2746. doi: 10.3760/cma.j.issn.0376-2491.2012.39.003

Weisinger RS, Stanley TK, Begg DP, Weisinger HS, Spark KJ, and Jois M (2009). Angiotensin converting enzyme inhibition lowers body weight and improves glucose tolerance in C57BL/6J mice maintained on a high fat diet. Physiol. Behav 98, 192–197. doi: 10.1016/j.physbeh.2009.05.009 [PubMed: 19465040]

Whitmer RA, Gunderson EP, Barrett-Connor E, Quesenberry CP, and Yaffe K (2005). Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ 330:1360. doi: 10.1136/bmj.38446.466238.E0 [PubMed: 15863436]

Widner B, Leblhuber F, Walli J, Tilz GP, Demel U, and Fuchs D (2000). Tryptophan degradation and immune activation in Alzheimer’s disease. J. Neural Transm 107, 343–353. doi: 10.1007/s007020050029 [PubMed: 10821443]

Wong TP, Debnam ES, and Leung PS (2007). Involvement of an enterocyte renin-angiotensin system in the local control of SGLT1-dependent glucose uptake across the rat small intestinal brush border membrane. J. Physiol 584, 613–623. doi: 10.1113/jphysiol.2007.138578 [PubMed: 17702818]

World Health Organization (2019). Dementia. World Health Organization. Available online at: https://www.who.int/news-room/fact-sheets/detail/dementia (accessed March 31, 2020).

Wright JW, and Harding JW (2010). The brain RAS and Alzheimer's disease. Exp. Neurol 223, 326–333. doi: 10.1016/j.expneurol.2009.09.012 [PubMed: 19782074]

Wright JW, Kawas LH, and Harding JW (2013). A role for the brain RAS in Alzheimer’s and Parkinson’s diseases. Front. Endocrinol 4:158. doi: 10.3389/fendo.2013.00158

Wu GD, Chen J, Hoffmann C, Bittinger K, Keilbaugh SA, et al. (2011). Linking long-term dietary patterns with gut microbial enterotypes. Science 334, 105–108. doi: 10.1126/science.1208344 [PubMed: 21885731]

Wu S-C, Cao Z-S, Chang K-M, and Jiang J-L (2017). Intestinal microbial dysbiosis aggravates the progression of Alzheimer’s disease in Drosophila. Nat. Commun 8:24. doi: 10.1038/s41467-017-00040-6 [PubMed: 28634323]

Yamada K, Uchida S, Takahashi S, Takayama M, Nagata Y, Suzuki N, et al. (2010). Effect of a centrally active angiotensin-converting enzyme inhibitor, perindopril, on cognitive performance in a mouse model of Alzheimer’s disease. Brain Res. 1352:176–186. doi: 10.1016/j.brainres.2010.07.006 [PubMed: 20627092]

Yang G, Jiang Y, Yang W, Du F, Yao Y, Shi C, et al. (2015). Effective treatment of hypertension by recombinant Lactobacillus plantarum expressing angiotensin converting enzyme inhibitory peptide. Microb. Cell Fact 14:202. doi: 10.1186/s12934-015-0394-2 [PubMed: 26691527]
Yano JM, Yu K, Donaldson GP, Shastri GG, Ann P, Ma L, et al. (2015). Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell 161, 264–276. doi: 10.1016/j.cell.2015.02.047 [PubMed: 25860609]

Yun SI, Park HO, and Kang JH (2009). Effect of Lactobacillus gasseri BNR17 on blood glucose levels and body weight in a mouse model of type 2 diabetes. J. Microbiol 107, 1681–1686. doi: 10.1111/j.1365-2672.2009.04350.x [PubMed: 19457033]

Zarrinpar A, Chaix A, Yooseph S, and Panda S (2014). Diet and feeding pattern affect the circadian dynamics of the gut microbiome. Cell Metab. 20, 1006–1017. doi: 10.1016/j.cmet.2014.11.008 [PubMed: 25470548]

Zhang L, Wang Y, Xiayu X, Shi C, Chen W, Song N, et al. (2017). Altered gut microbiota in a mouse model of Alzheimer’s disease. J. Alzheimer Dis 60, 1241–1257. doi: 10.3233/JAD-170020

Zhang LS, and Davies SS (2016). Microbial metabolism of dietary components to bioactive metabolites: opportunities for new therapeutic interventions. Genome Med. 8:46. doi: 10.1186/s13073-016-0296-x [PubMed: 25470548]

Zhang Y, Yu X-J, Chen W-S, Gao H-L, Liu K-L, Shi X-L, et al. (2016). Exercise training attenuates renovascular hypertension partly via RAS-ROS-glutamate pathway in the hypothalamic paraventricular nucleus. Sci. Rep 6:37467. doi: 10.1038/srep37467 [PubMed: 27881877]

Zheng H, Fridkin M, and Youdim M (2015). New approaches to treating Alzheimer’s disease. Perspect. Medicin. Chem 7, 1–8. doi: 10.4137/PMC.S13210 [PubMed: 25733799]

Zheng J, Li G, Chen S, Bihl J, Buck J, Zhu Y, et al. (2014). Activation of the ACE2/Ang-(1–7)/Mas pathway reduces oxygen-glucose deprivation-induced tissue swelling, ROS production, and cell death in mouse brain with angiotensin II overproduction. Neuroscience 273, 39–51. doi: 10.1016/j.neuroscience.2014.04.060 [PubMed: 24814023]

Zheng P, Zeng B, Zhou C, Liu M, Fang Z, Xu X, et al. (2016). Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host’s metabolism. Mol. Psychiatry 21, 786–796. doi: 10.1038/mp.2016.44 [PubMed: 27067014]

Zoccali C, and Mallamaci F (2014). Pleiotropic effects of angiotensin II blockers in hemodialysis patients: myth or reality? Kidney Int. 86, 469–471. doi: 10.1038/ki.2014.155 [PubMed: 25168498]
FIGURE 1.
Mechanisms of action and processes affected by communication of the gut microbiota with the CNS.
FIGURE 2.
Actions of the AT1R-mediated and MasR-mediated axes of the renin-angiotensin system (left) and known neuroprotective actions of Ang (1–7) in the central nervous system (right).
FIGURE 3.
Simplified schematic of human breakdown of tryptophan and influences on CNS signaling. Note that lactobacilli (the bacterial strain in our GMP) and the Ang (1–7) axis are active in this process.
| Rodent model | Age/Sex | Intervention | Duration of intervention | Main findings |
|--------------|---------|--------------|--------------------------|---------------|
| Torika et al. (2018) | 2 months/unknown sex | Intranasal ARB (Candesartan) | 8 weeks | Reduced hippocampal microglial activation and Aβ pathology |
| Trigiani et al. (2018) | 3-4 months/male & female | Oral or subcutaneous osmotic mini-pump ARB (candesartan) | 2–5 months | Lowered blood pressure, reduced neuroinflammation, increased dendritic arborization, and cellular proliferation but did not improve cognition or reduce Aβ pathology |
| Ongali et al. (2014) | 15 months/male & female | Oral ARB (Losartan) | 3 months | Losartan consolidates acquisition and recall memory, rescued cerebrovascular function; no reduction of Aβ pathology |
| Royea et al. (2017) | 3 months | Subcutaneous osmotic mini-pump ARB (losartan) | 3–4 months | Losartan improved memory retrieval, but not spatial learning, which was reversed by AT4R blockade. No alteration in Aβ pathology. |
| Mogi et al. (2008) | 2 months/male | Oral ARB (telmisartan or losartan) | 2 weeks | Telmisartan and losartan prevented intracerebroventricular Aβ-induced cognitive impairment, but only telmisartan improved Aβ deposition |
| Tsukuda et al. (2009) | 2 months/male | Oral ARB (telmisartan) | 2 weeks | Telmisartan improved cognition function, decreased tumor necrosis factor-α, and reduced Aβ concentration |
| Takeda et al. (2009) | 2 months/male | Oral ARB (olmesartan) | 4–5 weeks | Olmesartan attenuated cerebrovascular dysfunction without reduction of Aβ pathology. It also improved cognition, prevented vascular dysregulation, and partially attenuated impaired hippocampal synaptic plasticity in other mice |
| Ferrington et al. (2011) | 3–4 months/male | Oral ARB (eprosartan or valsartan) | 2 months | No change in Aβ or APP pathology |
| Ferrington et al. (2012) | 9–10 months/male | Oral ARB (eprosartan) | 6 months | No alteration in cognitive outcomes nor Aβ, tau, or APP levels |
| Wang et al. (2007) | 6 months/female | Oral ARB (valsartan) | 5 months | Reduced AD-type neuropathology and soluble extracellular oligomeric Aβ |
| Yamada et al. (2010) | 5-6 weeks/male | Oral ACEI (perindopril, imidapril, or enalapril) | 1 daily dose before testing | Only perindopril prevented working & long term memory deficits |
| Dong et al. (2011) | Not specified/male | Oral ACEI (perindopril, imidapril, or enalapril) | 7 days | Only perindopril prevented spatial memory impairment, prevented hippocampal macroglial & astrocytic activation, and attenuated oxidative stress |
| Torika et al. (2016) | 2 months/male | Intranasal ACEI (perindopril or captopril) | 3.5–7 weeks | Attenuated AD-associated markers in cortex, reduced hippocampal, & cortical Aβ burden |
| Ferrington et al. (2011) | 3 years | Oral ACEI (captopril) | 2 months | No change in Aβ or APP pathology |
| Ferrington et al. (2012) | 9–10 months/male | Oral ACEI (captopril) | 6 months | No alteration in cognitive outcomes nor Aβ, tau, or APP levels |
| Rodent model              | Age/Sex | Intervention                  | Duration of intervention | Main findings                                           |
|--------------------------|---------|-------------------------------|--------------------------|---------------------------------------------------------|
| AbdAlla et al. (2013)    | APP mutated mice | 12 months     | Oral ACEI (captopril or enalapril) | 6 months | Slowed Aβ plaque development and Aβ-related neurodegeneration |

3xTgAD, C57BL6 background mice with 3 AD-linked mutations; 5xAD, C57BL6 background mice with 5 AD-linked mutations; ACEI, Angiotensin-converting enzyme inhibitor; AD, Alzheimer’s disease; APP, Amyloid precursor protein; ARB, Angiotensin receptor blocker.